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Abstract
Our research is focused on the early and accurate detection of breast cancer (BrCa) by
molecular imaging. Breast cancer is the most common type of cancer among women. Each year
about one in eight women will be diagnosed, and over 500,000 deaths occur from breast cancer
globally. To improve chances of survival, breast cancer must be diagnosed and treated at an early
stage. Conventional imaging uses mammography, magnetic resonance imaging (MRI), and
ultrasound. Limitations in these can result in false-positive results or undetected tumors. It is vital
to create more sensitive imaging methods to diagnose BrCa, to reduce false-positives and to
guide therapy. A new approach to targeted molecular imaging agents (TMIAs) for BrCa will be
described for single-modal and dual-modal imaging by fluorescence and MRI. To target these
imaging agents, we employed a new BrCa-targeting peptide called 18-4. This peptide was
synthesized by solid phase peptide synthesis (SPPS) followed by conjugation of a near infrared
dye, Cy5.5-1S, utilizing a new modular method developed in our lab, to form M3, an imaging
agent for BrCa. The modular method was then utilized to construct a single-modal agent
containing the MRI-contrast agent metal gadolinium. Lastly, a dual modal targeted imaging agent
containing both Gd and Cy5.5-1S for dual modal fluorescence-MRI of BrCa was synthesized. This
is the first example of a dual-modal TMIA that is synthesized entirely by SPPS, where the imaging
agents are brought in on the side chain of amino acids that coupled as part of the solid phase
synthetic approach.
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AA (Amino Acids)
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Abbreviations of Amino Acids in peptide 18-4
Amino Acids
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Alanine

Ala
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Glutamic Acid

Glu

E

Glutamine

Gln

Q

Leucine

Leu

L

Lysine

Lys

K

Phenylalanine

Phe

F

Tryptophan

Try

W

Tyrosine

Tyr

Y

Norleucine

Nle

X
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Chapter 1. Introduction
1.1 Breast Cancer Background
It has been reported that each year globally, about 458,000 deaths occur from breast cancer
(BrCa).1 BrCa must be treated at an early stage to decrease the mortality rate.2 Cancer is caused
by genetic mutations of DNA and or RNA, which can occur under an unhealthy cell environment.3
Patients with a family history of BrCa are at higher risk for BrCa.4 Some other risks for BrCa include
age, genetics (abnormal gene mutations), being overweight, smoking, and lack of exercise.4 There
are two kinds of tumors, which include benign and malignant.5 The cells in a benign tumor are
non-cancerous and are not dangerous.5 Moreover, benign cells have a similar appearance to
healthy cells and do not metastasize (spread to other parts of the body).5 BrCa is known as a
malignant tumor that can metastasize.5
For BrCa, a staging system known as tumor-node-metastasis (TNM) is used for diagnosis.6
Staging is the analysis of the tumor’s (T) size and location.6 The second step of diagnosis is
determination of node (N), which identifies if the tumor has spread to the lymph nodes and how
many.6 Lastly, metastasis (M) or stage IV diagnosis is used to determine if the tumor has spread
to other parts of the body (lungs, liver, bones, brain, or chest wall).6 The process of metastasis
can occur by migration through circulation, where cancer cells travel to healthy cells by the lymph
vessels or blood vessels.7 The stage of BrCa or staging is used to identify the location, growth,
and spreadability of cancer.6
Utilizing this system, there are five stages of cancer, ranging from stage zero through stage
IV.6 A lower stage number indicates that it has spread less through the body.6 Stage zero is known
as noninvasive, which means that the tumor does not spread or damage other organs.6,8
1

However, stages I through IV are known to be invasive breast cancer.6 Stage I is known as a very
early stage, where cancer has grown larger within the breast, and the tumor can be up to 20 mm
large.8 Stage II is known as the localized stage, where the tumor has spread to the lymph nodes
and is about 20-50 mm in size.8 Stage III is known as the regional spread (larger than 50 mm),
where the tumor may have spread to more than one lymph node or the skin.8
Lastly, Stage IV is the most severe and is known as distant spread cancer.8 Currently, to
determine the stage of cancer, two diagnosis methods are used, including the clinical stage and
the pathologic stage.8 The initial step of diagnosis is the clinical stage, which uses a physical exam,
biopsy, and imaging testresults.8 Since the clinical-stage testing does lead to inaccurate results,
sometimes further testing is required.8 To determine the stage precisely, the pathologic stage is
used, a process that removes the tissue surgically for pathological testing.8
1.2 Current Imaging methods for breast cancer
While mammography and ultrasound are the primary diagnostic imaging methods for
detection of breast cancer, a more powerful imaging method for diagnosis of breast cancer is
magnetic resonance imaging (MRI), which uses a magnetic field, and radio waves.9
Mammography and ultrasound used in conjunction with MRI for confirmation and accurate
spatial mapping of BrCa. A significant advantage of MRI over other imaging diagnoses is that it
has minimal risks, in comparison to mammography, which has a risk for radiation.10 The x-rays in
mammography are known as ionizing radiation and in large amounts, can cause damage to cells
and lead to cancer.11 A limitation with the current imaging diagnosis of US, Mammography and
MRI is that these can result in false-positive results.12
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In a false-positive test result, the imaging method shows the benign tissue incorrectly to
be cancerous tissue.9 Therefore, such results can lead to further testing (MRI-guided breast
biopsy), which causes the patient to go through unnecessary pain and expense. Moreover, there
has been an increasing number of biopsies for breast cancer due to false-positive results.13 Also,
MRI screening is unable to determine the stage of BrCa in a patient due to the limited specificity.12
Therefore, it is essential to create efficient imaging methods to diagnose breast cancer and to
reduce the false-positive rate.12
In this study, the goal was to diagnose and pinpoint the location of breast cancer cells by
using targeting molecular imaging agents (TMIAs). The purpose of the TMIAs is to concentrate
the imaging agent at the site of cancer selectively Thus, with the use of TMIAs, MRI diagnosis will
be able to differentiate between cancer and benign tissues, which will rule out false-positive
results. Furthermore, this approach will improve the staging of breast cancer. Current staging by
for breast cancer requires further diagnosis such as removal of tissue via surgery.6,8 Addition of
TMIAs to MRI imaging will lead to a precise diagnosis for staging because the TMIAs will distinctly
identify cancer cells, including those which have spread to lymph nodes or throughout the body.
1.3 Molecular Imaging
Advancements in molecular imaging has provided new hope for early cancer detection,
cancer treatment, monitoring therapy response and disease recurrence in the future.14
Molecular imaging allows in vivo visualization and characterization of cellular biological
processes.14 Older technologies were able to only identify the structure and morphology of a
disease.14 Molecular imaging is able to identify biochemical and intracellular pathways, which
can help determine the disease development and progression.14 It is a therefore a means to
3

provide functional imaging. Using targeted probes for functional imaging we can extend the
question “what is there?” to “what is happening there?”
There are some advantages of molecular imaging compared to other imaging techniques.14
Molecular imaging can provide early cancer detection because it can evaluate cellular
abnormalities along with physical abnormalities, which can identify the stage of the disease.14
Also, molecular imaging can detect functional variation in tissue, which can potentially help with
identification of lesions.14 Lastly, in current imaging methods there is a limitation to the capability
of measuring the effectiveness of drugs. Molecular imaging can be used to advance this process
and has become a valuable tool in drug development and discovery.14 Moreover, another
advantage is that it can be used for gene therapy, where the genetic changes that are caused by
the treatment can be evaluated.14
Of the various imaging modalities available, optical molecular imaging (OMI), which is based
on fluorescence of dyes, is non-invasive and provides high sensitivity (single-molecule level) with
minimal invasion.14 Furthermore, OMI has low screening risk does not use ionizing radiation to
generate an image.14 A disadvantage of OMI is that whole body imaging is not possible. In OMI,
the probe is a visualizing agent that is used to characterize and quantify biological processes.15 A
probe may also be defined as a contrast agent, tracer, and molecular beacon.15 Probes for OMI
consists a fluorochrome, which is attached covalently by a linker to a targeting moiety that
ultimately provides a visualization method on the target of interest as shown in Figure 1.14,15
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Figure 1. Optical Molecular Imaging Probes15
Reprinted with permission from Chen,K.; Chen, X. Design and Development of Molecular Imaging
Probes. Curr. Top. Med. Chem. 2010, 10 (12), 1227.
Imaging probes can be made more effective by attaching to them a targeting moiety, which
binds selectively to a specific biological target of interest.15 In this study the targeting moiety is a
breast cancer peptide and the target is a breast cancer receptor. This will be attached to an
optical imaging probe to design a targeted molecular imaging agent (TMIA).
Molecular imaging probes have the advantage of high binding affinity to the target along with
high specificity to the target.15 The probes interact with only the specific target of interest, such
as a membrane receptor, an enzyme, or cellular DNA.15 Moreover, the highly specific binding can
reduce the uptake of non-specific biological molecules, which will help to quantify only the
targeted molecules in the cell.15
1.3.1 Confocal fluorescence microscopy (CFM) and NIR Dyes
Within the field of OMI, confocal fluorescence microscopy (CFM) is a microscopic technique
provides three-dimensional (3D) optical resolution.16 An advantage of CFM microscopy is that it
produces high-contrast images even with a thinly layered specimen.17 A laser beam is scanned
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across the sample (also known as point-by-point), which causes the fluorophores in the specimen
to absorb energy.16,17 As a result, the fluorophores fluoresce and emits light in the near infrared
(NIR) region of the spectrum at a longer wavelength (about 30 nm longer) than the excitation
wavelength.16,17 Moreover, near-IR fluorescence emission is ideal for in vivo imaging because it
has strong tissue penetration (1-2 cm).18,19
The wavelength range for NIR fluorescence imaging is from 700 nm to 1000 nm.18 The NIR
probes have good water solubility, which prevents the aggregation of the dye in tissues and
biological systems.18 There are two types of NIR probes, which includes inorganic and organic
molecules.18 Some of the inorganic NIR probes (nanometer-sized) used in vitro and vivo biological
imaging are quantum dots and nanoparticles.18 However, some nanoparticles such as quantum
dots have a disadvantage because the heavy metals ingredients (Cd, Se) can potentially lead
cytotoxicity (cell death).18 Moreover, nanoparticles have a disadvantage because they are
prepared at a small scale and are expensive.18 In addition, nanoparticles can exhibit non-specific
binding, thereby lighting up more than the tumor and in some cases the whole body.
Comparatively, small organic molecules (under 3,000 MW units), are ideal as a NIR probe and
can be synthesized at a larger scale.18 The organic NIR dyes are suitable to be conjugated
(covalently or noncovalently) with different biological molecules, which includes proteins, DNA
primers, amino acid, peptides, antibodies and nucleotides.18 There are some limitations to the
NIR conventional dyes, which includes poor depth penetration, poor hydrophilicity, and low
quantum yield.18 Dye types such as cyanine dyes, squaraines, phthalocyanines, porphyrin
derivatives, and BOD-IPY (boron dipyrromethane) dyes are newly developed organic NIR dyes
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that are used for biomedical imaging and have shown to improve fluorescence intensity and
sensitivity.18
A cyanine dye is an organic dye that is composed of two aromatic systems, which contain
heterocycles linked by a polymethine bridge. The two aromatic systems are known as indolenine
groups.18 Some of the common cyanine dyes (Cy) that are used for NIR fluorescence are
trimethine cyanine (Cy3, Cy3.5), pentamethine cyanine (Cy5, Cy5.5), and heptamethine cyanine
(Cy7, and Cy7.5).18,20 These dyes absorb at different wavelengths in the NIR region, where the
Cy3 dyes absorbs in the visible region and the Cy5 dyes absorb in the near-infrared region (>700
nm).18 A dye known as indocyanine green (ICG), absorbing between 600 and 900 nm and emitting
between 750 and 950 nm is a mainstay in OMI. With an established reputation in the clinic, many
cyanine dye systems have since been designed to emulate this, but with the added feature of
adding a functional group that enables joining the dye to a biological targeting system. Lastly, the
Cy7 dyes absorbs at 750 nm.18
Our molecular imaging lab collaborates with Dr. Ferran and Dr. Sweet from the Biology
department to produce confocal fluorescence microscopy (CFM) images for TMIAs. To label
peptides in our lab, the CFM dye used is known as the cyanine 5.5 (Cy 5.5) NHS ester dye. In
particular, the Cy 5.5 dye was chosen because the highest laser available at RIT for the CFM has
excitation at 633 nm, which has emission range between 650 nm and 750 nm. The difference
between Cy5.5, which is utilized for in-vitro imaging such as CFM, and Cy7 which is suitable for in
vivo imaging is shown in Figure 2. The main reason to utilize higher wavelength dyes such as Cy7
in animal studies is that they absorb light well beyond the absorption of Hemoglobin.
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Figure 2. Absorbance and emission spectra for Fluorescent Near Infrared (NIR) dyes,
maximum absorbance occurs at 680 nm
Apart from structural differences that result in different wavelengths, the cyanine dyes
are divided into two groups based on solubility, which includes non-sulfonated and sulfonated
dyes.20 And both are used to label biomolecules, such as proteins and DNA.20 A disadvantage to
the non-sulfonated cyanine dye is that they have low aqueous solubility.20 The sulfo-dyes are
water soluble and the of addition of a sulfonate group (SO3-) at the aromatic ring facilitates the
solubility of the cyanine dye in aqueous phase.20 The negative charge of on the sulfonate group
decreases the aggregation of the dye molecules in water.20 In particular, the single-sulfonated
cyanine 5.5 (Cy 5.5-1S) dye was used in this study as shown in Figure 3.
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Figure 3. Structure of Cyanine 5.5 (1S) dye and Cy 7.
1.4 Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) is a tomographic imaging technique commonly used in
medical clinical practice.21 In 1952, Bloch and Purcell were awarded the Nobel Prize for
discovering the magnetic resonance phenomenon.22 A MRI scanning machine was introduced by
a physician Damadian and later in 1969 he was the first to perform a full human body scan to
diagnose cancer.23 Moreover, Damadian discovered MRI distinguishes between tumors and
normal tissue because they have different relaxation times.23 MRI generates three-dimensional
(3D) images and is noninvasive and unlike other imaging techniques MRI is considered a safe
imaging method because it does not use ionizing radiation.24
All of the components on MRI scanner are controlled by the computer.21 The MRI scanner is
composed of three main components, which includes large magnet, gradient coils, and radio
frequency (RF) coils (shown in Figure 4).21 To image the body, MRI uses a strong magnetic field,
which is ten thousand times greater than the Earth’s magnetic field.24
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Figure 4. Schematic representation of MRI Scanner21
Reprinted with permission from Hornak. J.P. The Basics of MRI; Interactive Learning Software,
Henietta, NY, 2012.
The type of magnet used in MRI is known as the superconducting magnet, which is an
electromagnet composed of superconducting wire.21 Liquid helium is used to cool the
superconducting wire to absolute zero (0 K).21 To produce an image MRI produces a magnetic
felid (B0) at about 1.5 to 3 Tesla.21,25 Moreover, there are gradient coils in the MRI that are at
room temperature, which are within the magnet that produce B0 in the X, Y, and Z directions.21
Lastly, in the MRI scanner the RF coil are present within the gradient coils.21 A B1 magnetic field
is produced by the RF coil, which is used to rotate the spins by 90°, 180° in the XY plane.21
The imaging property responsible for MRI is water and fat present in the human body.21
Water and fat molecules are abundant in hydrogen atoms (approximately 63% in the body).21
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Mainly the nuclei of the hydrogen atom is responsible for producing an NMR signal.21 The
hydrogen atoms have a property known as nuclear spin.21,26 When there is no magnetic flied
present the hydrogen spins are randomly aligned in the body.26 However, after MRI provides a
strong magnetic felid (B0) the spins of the protons are aligned with magnetic field.26
Firstly, the nucleus of the protons has angular momentum and it spins or rotates around
the B0 axis, called precession, which results in a net magnetization.21,26 The rotation velocity or
rate around direction of the protons is known as the Larmor frequency.26
Secondly, the protons that have a nuclei spin are excited with a second radio frequency
(RF) magnetic field B1, which is applied perpendicular to the external magnetic field (B0).26 When
a RF is applied in short pulses, which last about microseconds.26 The energy level of the nucleus
transitions from higher to lower energy from the process of absorption. After the radiofrequency
is turned off, it results in magnetic vectors to return to the resting state, which results in a
relaxation signal that can be detected.26 The process of relaxation occurs when after the
absorption of the RF pulse, the nuclei spin returns to thermal equilibrium.26 The precession
magnetization from the RF coil generates a radio wave, which is known as the free induction
decay (FID) time domain signal.26 The RF pluses are applied multiple times, which generate
multiple FIDs and as a result the FIDs are averaged to enhance signal-to-noise ratio (SNR).26 Lastly,
to obtain an MRI image the signal-averaged FID is transformed by a method called Fourier
transformation.26 An image is derived from software manipulations of this Fourier transform and
various tissues are depicted in different shades of color.
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Chapter 2. Modular Approach
2.1 Modular approach for Imaging Agent Synthesis
Targeted molecular imaging agents (TMIAs) are synthesized by coupling amino acids with
imaging agents attached to the side chains.27 The peptide-based TMIAs can be synthesized with
amino acids that have a combination of single-modal or dual-modal metals and dyes, which can
be attached in first or last step of the synthesis.27 Our lab’s focus is to provide medical researchers
with ready to access single or dual modal TMIAs. In our lab, a new approach to synthesize TMIAs
was developed, which is known as the modular method. Using modular method offers many
advantages, where dyes and metals can be mixed and matched.

Figure 5. Past approach for the synthesis of TMIAs using solution phase28
In the modular synthesis, a puzzle piece is synthesized first. A puzzle piece is composed
of an imaging group (metal or dye) placed on the side chain of lysine group (shown in Figure 5).
Previously, to synthesize a TMIA, the modular method was used, where the two imaging modules
are coupled first. Following the coupling of imaging agents, a linker group such as disuccinyl
suberate (DSS) is added (as shown in Figure 5). Lastly, the targeting group is coupled on the left
side is conjugated to this system. The targeting group can be any drug, antibody, or peptide. In
our group the past TMIAs that have been synthesized were by solution phase peptide synthesis,
which has some disadvantages.28 In solution phase synthesis, each intermediate at every step
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requires purification, which is a time-consuming step.28 Moreover, dyes may degrade during the
purification process and also the additional purification steps lead to a lower yield.28
Some of the imaging agents that can be attached to peptides include those developed for
confocal fluorescence microscopy (CFM), Near-infrared (NIR), MRI, Positron-Emission
tomography (PET), and Photoacoustic Imaging (PAI).28 The main goal of this study was to
synthesize TMIAs composed of the MRI contrast agent gadolinium (Gd) and the NIR (Cy5.5-1S)
dye as (shown in Figure 6).

Figure 6. Current approach for the synthesis of TMIAs using solid phase28
Also shown in Figure 6, in this study, the TIMA was synthesized in the opposite direction.
The BrCa targeting agent (a peptide) was synthesized first, which was followed by attaching the
imaging agents (Gd agent and Cy5.5 dye) last. This synthesis stems from the targeting peptide
and since the imaging modules are amino acids, it allows to make a longer peptide where the last
two amino acids are the imaging modules.
Furthermore, in this case, solid phase peptide synthesis (SPPS) was used to produce the
TMIA because it has many advantages. The SPPS is a faster synthesis process because there is no
need to purify each intermediate, therefore is not a lost in yield. It is a much-preferred method
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in peptide synthesis, because it allows us to marry the imaging agent and peptide chemistry
together in an efficient manner.
2.2 Single and Dual-Modal Imaging
TMIAs can be synthesized as single-modal, dual-modal, or multi-modal imaging agents.
As shown in Table 1, there are advantages and disadvantages of single modal MRI and
fluorescence imaging.29 Single modal fluorescence imaging (FI) alone is not useful for breast
cancer diagnosis because FI has low temporal and spatial resolution.29 However, FI is suitable for
diagnosis because it has tissue penetration up to 1-2 cm deep) and is favorable because it has
high sensitivity and high specificity.29 Unlike many techniques in imaging, FI is conducted with
relatively inexpensive instrumentation.
Table 1. Fluorescence and MRI Advantages and Disadvantages30

Spatial Resolution
Sensitivity
Penetration Depth
Traumatic

FI
Low
High
Shallow
Noninvasive;
Nonradioactive

MRI
High
Low
Deep
Noninvasive;
Nonradioactive

FI has the ability of obtaining detailed biological information at a subcellular level.29
Compared to other imaging techniques FI has a major advantage because it can be used during
surgery. Doctors could use fluorescent cancer markers during a lumpectomy (removal of breast
tumor), where the laser light is used to light up the targeted cancer cells and remove the tumor.30
MRI is used to view internal anatomical structures and tissue, a produces high contrast
images.29 Compared to FI, which generates blurry images, MRI has the advantage of producing
clear and detailed morphological images with high spatial resolution.29 But MRI is not very
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sensitive. A major advantage of MRI over FI is that MRI is used for breast cancer diagnosis because
it has deep tissue penetration.29
In molecular imaging, combining different modalities can be advantages because it can
produce complementary information over single modal alone.29 Dual modal is a powerful
technique for disease diagnosis and treatment that will improve detection sensitivity and
accuracy.31 To synthesized a dual-modal TMIA, two different imaging agents are combined to
produce one imaging agent. Using single-modal fluorescence agent for FI is limited with tissue
penetration and is not useful for diagnosis but is useful for surgery and remove cancer at the
site.29 However, the combination of both MRI and FI will provide quantitative and tomographic
information.31
In the past FI/MRI dual-modal imaging probes have been synthesized and applied in
clinical practice.29 The dual modal FI-MRI agents that have been synthesized were derived from
nanoparticles, which have many disadvantages. 29Nanoparticles can bind non-specifically in the
body, especially in the liver and kidneys.29 Also, nanoparticles are much larger in size to be used
as a drug.29 Moreover, due to the large size of nanoparticles they have poor tissue penetration
and can only tag the surface of the tissues.29 Lastly, nanoparticles have a disadvantage as TMAI
because many types of nanoparticles cannot accumulate inside of tumor as efficiently as small
molecules for amplification of tissue detection.29
To make dual-modal imaging agents, another reported study has combined a NIR dye with
chelated gadolinium-based MRI contrast agent.31 However, the imaging agents synthesized in
this report was not targeted for cancer cells.29 The agent instead relied on increased illumination
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in an acidic environment. Since the interior of cancer cells are acidic, it was proposed to light up
the cells using dyes that are non-targeted, but can change color based on changes in pH.
In contrast to this approach, our approach is based on dual-modal imaging agents which
can be molecularly targeted specifically to breast cancer cells by utilizing an agent that is known
to bind selectively to membrane receptors on those cells.
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Chapter 3. Cancer Treatment
3.1 Current Treatment of Breast cancer
A stretch goal of this study was to treat cancer by the use of related TMIAs, synthesized
by a similar route. This is a project currently being carried out in our lab by Sara Shaut and Matt
Law. Conventional treatment for cancer is chemotherapy, which uses chemotherapeutic
agents.32 Chemotherapeutic agents can inhibit the rapid growth of cancer cells.33 However, a
significant disadvantage of chemotherapy is the potential risk of uptake by healthy cells.33,34 The
cell death from chemotherapy treatment can occur in many organs in the body, which includes
the heart, kidneys, bladder, lungs, and nervous system.33
Another issue with the current drug delivery is the uncertainty of the chemotherapy
agents’ binding specificity; they should bind only to the breast cancer cells.32 The agents are not
selective for cancer cells, and therefore they don’t particularly accumulate at the site of cancer.34
By use of a TMIA, the agent will only attach at the cancer site and protect the healthy cells due
to the binding specificity of the TMIAs. In the future, fluorescent TMIAs, several of which are in
development now, will be used to assist in “light directed surgery”. The agent can be given to the
patient before surgery, which will light up only the cancer cells allowing for directed treatment.
3.2 Photodynamic Therapy (PDT) for cancer
A new method known as photodynamic therapy (PDT) is used to treat cancer.35 An agent
known as photosensitizing (PS) agent is injected, which is absorbed into the cells all over the
body.35 The purpose of the photosensitizing agent also known as a photosensitizer (drug) is to kill
the cancer cells upon the exposure to a laser light.36 However, the non-targeted photosensitizing
agent can remain in normal cells in approximately 24 to 74 hours.35 Also, PDT has shown to
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damage tumor blood vessels, which prevents cancer because cells become deficient of
nutrients.35
3.2.1 Photosensitizer mechanism for killing cancer cells
The electrons are unstable energy in the excited state (shown in Figure 7), and return to
the ground state by emitting a photon and this process is known as fluorescence.37 Radiative
transition is described as the absorption or emission of photon, demonstrated as straight lines.37
Non-radiative transitions are described as the energy transferred between different degrees of
freedom of a molecule or to the surroundings, demonstrated as wavy lines.37 Fluorescence and
phosphorescence occur as radiative transitions.37 Nonradiative transitions include, intersystem
crossing, internal conversion, and vibrational relaxation.37

Figure 7. Jablonski Diagram that shows the formation of reactive oxygen species (ROS) induced
from photosensitizer agent38
Reprinted with permission from Abrahamse, H. New Photosensitizers for Photodynamic Therapy.
Biochem. J. 2016, 473 (4), 347.

18

Due to collision of the electrons in the excited state there is a loss of energy through the
transitions, which causes the emission wavelength in fluorescence to be longer than the
excitation wavelength.37
In the ground state the photosensitizer is a singlet since it is composed of two electrons
with opposite spins.38 The electrons in the photosensitizer transition from the singlet state (lowenergy orbital) to the excited state (higher-energy orbital) by absorbing energy from a photon
(light).38 The photosensitizer is unstable in the singlet excited-state, which causes it to lose energy
and that can through the process of fluorescence (emission of light) or internal conversion (heat
production or non-radiative decay).38 The process of phosphorescence is the transition of the
electrons from the triplet state (more stable) to the ground state, which occurs at a longer life
(microseconds).38 The photosensitizer transitions of the electrons do not occur with the
phosphorescence but with intersystem crossing, which causes a stable excited triplet state
(parallel spin).38
There are two types of chemical process that occur for the photosensitizer molecule, and
that includes the Type I photochemical and Type II photochemical process.38 In the Type II
photochemical reaction, the electrons in the triplet state collide with molecular oxygen (O2) in
the cell, and energy is transferred due to the longer lifetime of the triplet state.38 Upon collision
of the electron a reactive singlet oxygen (O2•) is formed, as shown in Figure 7.38 In Type I
photochemical reaction an electron transfer reaction leads to form a reactive oxygen species
(ROS).38
The photosensitizer is successful is killing cancer cells because ROS is toxic to cells.39 In
the body, free radicals cause to the damage from a process known as oxidative stress. In this
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study, a photosensitizer will be used to treat breast cancer and only the cancer cells will be killed
because of the targeting agent present in the TIMAs. Breast cancer cells treated with the
photosensitizer will be treated with a laser to kill the cells. Lastly, the treatment analysis will be
done in the future by MRI and CFM to ensure that the cancer cells died.
While this stretch goal did not become part of this research, the synthetic methods
developed in this study can be applied to the attachment of other dyes, including photosensitizer
(PS) dyes to peptides in much the same manner as imaging dyes reported here. The same
technique of attaching the puzzle piece containing the dye onto the growing peptide chain in
SPPS could be applied to attaching PS dyes to produce targeted agents for PDT of BrCa.
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Chapter 4. Peptides as Targeting Molecules
4.1 Peptides Advantages and Disadvantages
Previously, studies have shown that peptides can be used as targeting molecules and in
addition, they have many advantages.32 A significant advantage is that peptides are small and
compact (1000-3000 amu), which allows them to circulate throughout the vascular system easily
and penetrate the cells quickly.28 Another advantage of using peptides as TMIAs is due to their
clearance properties.40 The clearance property of a drug is the ability of a drug to be excreted
from the body.40
The process by which peptides enter the cell is known as endocytosis, where the cell
ingests large particles from the extracellular environment.41 The process of endocytosis occurs in
two steps, initially the peptide binds to the receptor of the BrCa cell.42 The binding location of
the peptide to the cancer cells occurs at the receptor site of the cell.42 The receptor known as
keratin-1 (KRT1) on the breast cancer cells is recognized by the targeting agent (peptide) and
attaches to it.42 Lastly, the cell targeting agent is engulfed into the BrCa cell.41,42
Moreover, the peptide includes simple design and practical synthesis. Peptides are made
up of individual amino acids (AA), which contain a carboxylic acid group, an R group, and a
hydrogen atom.43 For example, two AAs bonded with a peptide bond is known as a dipeptide.43
The left side of the peptide is known as the N-terminus (amine end), and the right side of the
peptide is known as the C-terminus (carboxylic acid end).43 Lastly, the synthesis of peptides is
practical, since one amino acid can be added to the peptide at a time.
Another advantage of using peptides as TMIAs is due to bioavailability characteristics and
their clearance properties.40 Upon injection, peptides naturally circulate in the bloodstream and
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can readily enter tissues and readily bind to membrane rectors. Small peptides under a molecular
weight of 3,000 are most idea in this regard. While an orally available drug should be under a
MW of 500, an injectable imaging agent of MS 3,000 or smaller is still advantageous over larger
agents such as antibodies or nanoparticles in terms of bioavailability and clearance properties.
However, a significant disadvantage of peptides is that they can otherwise degrade in the
body naturally through a process known as proteolysis.32 The enzymes that are responsible for
the degradation (or cleavage) of the peptides are proteases (found naturally in the body),
including trypsin and chymotrypsin.28 These are prevalent primarily in the digestive system but
also in the bloodstream. Specifically, the cleavage occurs at the peptide bond, which is a linkage
of an amide bond to a carboxyl group in a peptide. A peptide that doesn't undergo the process
of degradation, or proteolysis, is known to have proteolytic stability.
Fortunately, the process of proteolysis can be stabilized by synthesizing incorporating D
amino acids in key locations on the peptides through the method known as solid-phase peptide
synthesis (SPPS).44 All amino acids exist naturally in the L-residue form (natural form), which
commonly leads to degradation in the body.44 In natural peptides, the amino is recognized by the
proteases, which leads to the cleavage of the peptide.
4.2 Peptide Nomenclature and Stereochemistry
In SPPS, peptides may be synthesized to incorporate the unnatural D form of an amino.32
The peptides that are synthesized with D-amino acids in critical positions will have increased
proteolytic stability because the protease enzyme does not recognize D-residue (unnatural form)
peptides.32 The side chain of an amino acid in a natural peptide (all L amino acids) is depicted by
the following stereochemistry: when the angle of the two bonds to the side chain carbon is a up,
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the natural stereochemistry is shown by a solid wedged line (out of the page), and when the
angle made by the same to bonds to the side chain carbon is down, the natural configuration is
dash wedged line (behind the page).32 When peptides that are synthesized with SPPS are contain
unnatural amino acids, as shown in Figure 8. The stereochemistry of the R group is the opposite,
replacing the solid wedge up with dash and when in the down position, the dashed wedge is
replaced by a solid wedge down.32

Figure 8. Peptide Nomenclature. Unnatural AA’s are denoted as D (dLys) and lower case
in one letter
4.3 Stereochemistry and Stabilization of Peptide 18-4 against proteolysis.
Previously, at the Chapman University, Dr. Kaur was successful at synthesizing a peptide
with SPPS that had proteolytic stability.32 As shown in Figure 8, peptide 18-4 has two unnatural
amino acids that are D-residue, which includes norleucine and lysine.32 These two positions
imparted strong stability against proteases. It was determined that the peptide 18-4 (D-residue)
did not undergo degradation in the presence of proteases, because the enzymes in the body do
not recognize the unnatural peptides.42 It is often necessary to only change the stereochemistry
of amino acids involved with peptide bonds that are more vulnerable to proteolysis.
Furthermore, D- amino acids can impart stability to peptide bonds in each direction.
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Figure 9. Peptide 18-4 (H-Trp-dNle-Glu-Ala-Ala-Tyr-Gln-dLys-Phe-Leu-NH2) synthesize by SPPS32
Furthermore, the binding specificity of the targeting agent to the breast cancer cells was
tested in mice in Dr. Kaur’s study.32 Mice with breast cancer tumors were treated (intravenously)
with the targeting agent.32 The results confirmed that the peptide specifically bound to the tumor
site and not to healthy cells.32 It was concluded that the peptide has high-affinity binding for the
breast cancer cells.
In Dr. Kaur’s study, the ability of peptide degradation (proteolytic stability) was examined
by placing the synthesized peptide 18-4 (D-residue) in human serum, and assaying the lifetime of
the intact peptide by HPLC.32 The results established that the peptide 18-4 was resistant to
degradation.32
4.4 Peptide 18-4 as a Selective Targeting Molecule
As a result, peptide 18-4 is a selective targeting molecule for breast cancer because it can
be easily taken up by the cancer cells. In this study, peptide 18-4 was synthesized and used as a
targeting molecule. An advantage of the synthesized peptide 18-4, also known as decapeptide
(10 amino acids) is that it has enhanced bioavailability.32 Drug bioavailability is the concentration
of drug that reaches the bloodstream.45
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Dr. Kaur began on the studies with peptides that were composed of 12 amino acids, which
resulted in lower bioavailability due to size.32 With the goal of increasing bioavailability and
decreasing size, Kaur reduced the size by eliminating non-essential amino acids. The results led
to peptide 18-4 which was smaller in size, increased in proteolytic stability which would led to
higher bioavailability.32 Essentially the primary responsibility of the target molecule (peptide 184) is to deliver the imaging agent to the cell, then hopefully undergo endocytosis to accumulate
inside the cell.
In further studies, Kaur found that the 18-4 bound to several types of BrCa cells including
TN cancel cells including MDA-MD-231, MDA-MB-435, and MCF-7. Moreover, these cells resulted
in a higher affinity for the 18-4 peptide.
4.5 Preliminary CFM Results
One of the methods used to treat breast cancer is known as cancer hormonal therapy,
which includes three hormones, estrogen, progesterone, and HER2.46 In triple-negative breast
cancer, the receptors for all three hormones are tested negative.47 The three hormones used to
inhibit the growth of tumor, and triple-negative breast cancer are ineffective by treatment by
any of the three-hormones (hence the name triple-negative).47 Furthermore, triple-negative
breast cancer is the most aggressive cancer because it metastasizes faster and has a higher
chance of spreading.47 In our design, it was hypothesized that TMIAs based on 18-4 will bind to
the triple-negative breast cancer (MDA-MD-231 BrCa) cells as well as the hormone receptor
active lines MCF-7.
The TMIA, Cy5.5-18-4 or M2, synthesized in our lab, was tested with CFM in our Biology
department at RIT by Dr. Irene Evans. The cellular uptake of the TMIAs into the breast cancer
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cells was be tested by growing MDA-MD-2331 BrCa cells in-vitro. Non-cancerous cells were used
as a control, and it was expected that in CFM they will not fluoresce (light up) because the cells
will not take up the TMIAs.

Figure 10. CFM images of Triple negative MDA-MD-2331 BrCa cells stained with M2
TMIA in collaboration with Dr. Irene Evans, GSOLS, RIT
It was predicted that the cancerous cells should fluoresce because the TMIAs bind only to
the cancer cells specificity. The imaging of the breast cancer cells were found to indeed increase
in fluorescence intensity compared to the normal cells), as shown in Figure 10. The magnification
of the MDA-MD-231 cells stained with the M2 TIMA clearly showed endocytosis, a mechanism
whereby the imaging agent is engulfed by the cell membrane and is internalized into the cell. The
red color indicates the fluorescence where the TIMA is bound in the cell. The blue color indicates
the breast cancer cell nuclei, which occurred from staining by Nuc blue. The CFM image of the
cancer cells verified the hypothesis, that the 18-4 peptide – Cy5.5 conjugate selectively binds to
the breast cancer cell receptor KRT1 found on the cell membrane. This had been observed earlier
with a similar agent by Dr. Kaur, but it was important to verify this in our own lab with our own
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agent. It is our further hypothesis that by accumulation of the TMIA inside the cell that the
fluorescence intensity should be amplified versus TIMA’s that are bound to the membrane only.
4.6 Solid Phase Peptide Synthesis (SPPS)
A peptide is defined as flexible long chain with 2-50 amino acids, which can be part of a
protein structure naturally in the body or a stand-alone biomolecule such as a
neurohormone.44,48 Solid phase peptide synthesis (SPPS) is step-wise coupling reaction that
results from the formation of a peptide bond between two amino acids.48 There are several
advantages of solid phase chemistry: the reactions are simple, fast and all reactions are carried
out in a single reaction vessel.44 Secondly, solid phase chemistry is efficient because large amount
product is not lost through isolation and purification of intermediates.44 Moreover, in solid phase
byproducts or excess reactants can be removed during the washing step.28,44 Through this
process another large advantage is that peptides prepared by SPPS can be exceedingly pure (well
above 95 % pure) even after multiple-step syntheses.
In this study SPPS was used to synthesize a BrCa peptide known as 18-4 (decapeptide).
The SPPS method was initially developed in our lab by Xinyu Xu and Matt Law. After a ten-step
synthesis it is remarkable that a pure product and good yield was obtained, which is a major
advantage of the SPPS. An overview and a step-by-step of the coupling reaction for the synthesis
of 18-4 peptide by SPPS is shown in Scheme 1. The amino acids are shown in a three-letter
abbreviation, and in this synthesis one amino acid was coupled at a time until the final
decapeptide was achieved. Also, some amino acids require a protecting group (shown in red
below). At the end of the synthesis all the protecting groups and the polymer attached were
removed with acid.
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Scheme 1. Solid Phase synthesis (SPPS)- developed by Xinyu Xu, Matt Law and Basant
Kaur28
Step-by-step SPPS of the first three amino acids found in the BrCa 18-4 peptide is shown
in detail in Scheme 2. The peptide is synthesized by a coupling mechanism of the amino acids
from the C-terminal (right side of the peptide chain) to N-terminal (left side of the peptide
chain).48 The initial step of the synthesis requires the following reactants: an amino acid with the
fluorenylmethyloxycarbonyl chloride (Fmoc) and an amine group on the resin (polymer).48 The
Fmoc is a protecting group, which is used to protect the nitrogen on the amine functional group
(which is on the amino acid) from reacting in the solution.48
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Scheme 2. Solid Phase Peptide Synthesis (SPPS) of first tripeptide in 18-428
In the first step the polymer and first amino-acid is coupled, where the free acid group is
activated, then reacts with the free amine on the polymer (shown in Scheme 2).48,49 The second
step of SPPS is known as the deprotection step, where the Fmoc group attached with the amino
acid is removed.49 The Fmoc group is stable in acidic conditions, and is removed by a weak base.50
To remove the Fmoc group a secondary amine known as piperidine is used, which results in a
free N-terminus amine.28 The coupling process is continued by the addition of an amino acid to
the free N-terminus amine.28 The following steps including coupling, deprotection, coupling of
next amino acid, which leads to the elongation of the peptide.49 In the final step the resin is
cleaved from the peptide and in this study, the process of SPPS was used to prepare the breast
cancer peptide 18-4 (H-Trp-dNle-Glu-Ala-Ala-Tyr-Gln-dLys-Phe-Leu-NH2), which is also known as
the targeting agent as shown in Figure 9.
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In this study, reverse phase-high performance liquid chromatography- mass spectrometry
(LC-MS) was used to test the purity of the peptide 18-4. HPLC can separate a mixture based on
polarity, electrical charge, and molecular size.51 In RP-HPLC, the mixture is separated according
to polarity.51 The column in the RP-HPLC contains two phases, the stationary phase (packing of
the column) that is nonpolar and the mobile phase (aqueous solution) that is polar.51 The HPLC
chromatogram was used to determine the different fractions of peptide 18-4 present in the
sample. The mass spectra gives a precise measurement of molecular mass in the electrospray
positive (ES+) spectra. If the sample is multiply charged, as often happens, it appears at the “half
mass” according to the formula (M+n)/n. Our peptides are often seen at M+2/2 due to
protonation at two sites.
To fully utilize LC-MS characterization, our group has developed a “micro-cleavage” HPLC
assay at each step during the SPPS. In the past, peptide chemist generally carried out the
synthesis to completion and evaluate the intermediates on the resin by a colorimetric test which
indicates the presence of a free amine after the coupling reaction to ensure its completion.
Micro-cleavages ensured the identification of the intermediate products along the way in the
synthesis of 18-4 peptide, and confirmed that not only is there no free amine of the prior peptide,
but that the protecting groups are intact, and that complete coupling has occurred. This allows
conformation of complete coupling which provides the confidence to continue the synthesis to
the next step. The detailed steps and methods of the SPPS reactions will be explained in the
following sections.

30

Chapter 5. Solid Phase Peptide Synthesis Methods
5.1 Selection of Resin Material for SPPS
The most common acid linker resin in SPPS is known as the Wang resin, which requires
concentrated TFA (90-95%) for peptide cleavage.52 The Wang resin afford the C-terminal acid
group. When a C-terminal amide is required, the Rink amide resin is most often utilized. Some
other resin used are rink acid, 2-chlorotiyl chloride, hydrazine, and sulfonamide.44 Some factors
that are important to consider when selecting a resin for SPPS induces, loading levels, swelling
capacity, peptide product (acid, amide, ester, alcohol, and hydrazide), and cleavage
conditions.44,52

Figure 11. Structure of Sieber resin28
In Dr. Kaur’s work, she used Rink resin for the BrCa 18-4 peptide synthesis, which requires
strong TFA cleavage conditions. The TMIAs that we synthesize in our lab contain near infrared
dyes (NIR dyes) and MRI contrast agent (Gd), which are not stable in pure TFA and can decompose
in strong acid conditions.28 In our lab, Xinyu Xu discovered that the Sieber resin is the most
efficient for our TMIA synthesis.28 In the past, it was discovered that the NIR dyes are stable in 12% TFA conditions.28 For all our TMIAs synthesis we used the Sieber resin, which can be cleaved
with 1% TFA and is a suitable condition for the NIR dyes. Figure 11 shows the structure of the
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Sieber resin, which is a mild acid-labile linker and is composed of an amine protected by an Fmoc
group.28
5.2 Fmoc Deprotection Mechanism
In SPPS, a common protecting group that is used to protect the backbone N-terminal
nitrogen from reaction in solution is known as fluorenylmethyloxy carbonyl (Fmoc).28 The Fmoc
group is used in organic synthesis and is known as base-labile protecting group, which can be
removed under mild basic conditions such as piperidine.48
In a more recent development in our lab, to remove the Fmoc group, 2% of 1,8Diazabicyclo [5.4.0] undec-7-ene (DBU), 5% of piperazine and 93% of DMF was used.28 The
deprotection of the Fmoc group is shown in Scheme 4. The mechanism is shown below, where
the hydrogen located on the β-carbon is highly acidic, therefore a week base such as piperazine
plucks the hydrogen and causes the cleavage to occur (CO2 is formed as a byproduct).53

Scheme 3. Mechanism of Fmoc Deprotection28
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5.3 SPPS Step-by-Step Guide for Breast Cancer Peptide 18-4
An in depth step-by-step experimental guide for the SPPS used to synthesize the BrCa 18-4
peptide is shown below. This method was originated in our molecular imaging lab (MIL) by Xinyu
Xu and optimized further in the present study. For each step in SPPS, the resin and solvent scale
is shown in Table 2. The following recipe below includes main synthesis in this research which
started with 850 mg scale of Sieber resin.
Table 2. Resin and solvent scale for SPPS (The steps refer to the sections below).
Resin

Step 1, 3,5- DMF Step 2- Deprotection

Step 4- DMF to Step 8- 1% TFA for

(mg)

and

for 5 min

HATU and AA

30 min

Step

7-

DCM

Wash

100

2 mL for 30 sec

1 mL

2 mL

1 mL

400

8 mL for 1.5 min

4 mL

8 mL

1 mL

500

10 mL for 2 min

4 mL

10 mL

1 mL

850

16.5 mL for 2.5 8.5 mL

16.5 mL

1 mL

20 mL

1 mL

min
1000

20 mL for 3 min

10 mL

33

5.3.1 SPPS Recipe: Step 1. Pre-Swelling
Obtain the initial mass of a large reaction vessel and a stir bar. Weigh out exactly 850 mg of the
Sieber resin and transfer it to the SPPS vessel.28 To begin the pre-swelling process, add 16.5 mL
of N,N-Dimethylformamide (DMF) into the reaction vessel by a syringe.28 Allow the resin to stir
for 20 minutes and drain the vessel using air pressure.28 Note the pre-swelling step is only
required for the before the first amino acid is added. Following the addition of the first amino
acid, wash the reaction vessel with 16.5 mL of DMF for 2.5 and repeat the washing step for 2
more times.
5.3.2 SPPS Recipe: Step 2. Fmoc Deprotection
To make 100 mL of the Fmoc Deprotection solution mix the following into a brown glass bottle,
2% of 1,8-Diazabicyclo [5.4.0] undec-7-ene (DBU), 5% of piperazine and 93% of DMF (shake well
before use).28 Add 8.5 mL of the Fmoc deprotection solution into the reaction vessel and allow it
to stir for 5 mintues.28 Repeat the Fmoc deprotection for two more times for 5 minutes each. The
Fmoc deprotection step is repeated total of three times for 15 minutes in total to ensure that all
of the resin is completely deprotected.
5.3.3 SPPS Recipe: Step 3. Washing after Deprotection
To ensure that the reaction vessel environment does not contain the basic Fmoc deprotection
solution, the resin is washed with DMF.28 For 850 mg of resin, add 16.5 mL of DMF to the reaction
vessel, stir for 2.5 minutes and drain the DMF.28 Repeat the washing step of the resin with the
DMF 2 more times for 2.5 minutes each.28
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5.3.4 SPPS Recipe: Step 4. Coupling Amino Acids
Tare a 20 mL scintillation vial, weigh out 2.0 equivalents of the first amino acid in the BrCa 18-4
peptide.28 In another 20 mL scintillation vial, weight out 1.9 equivalents of
[Bis(dimethylamino)

methylene]-1H-1,2,3-triazolo[4,5-b]

pyridinium

(13-oxid

hexafluorophosphate) or HATU, the coupling reagent used in SPPS.28 To dissolve the amino acid
and the HATU in solution, to each scintillation vial add 16.5 mL of DMF.28 Next, to the vial
containing the amino acid, add 10 equivalents of N, N-Diisopropylethylamine (DIEA) and shake
well.28 Lastly, transfer the HATU mixture into the amino acid vial (containing the DIPEA) and stir
for about 5 minutes. Lastly to couple the amino acid to the resin, add the activated solution to
the reaction vial and stir for 45 minutes.28
5.3.5 SPPS Recipe: Step 5. Washing after Coupling
After 45 minutes of stirring, drain the reaction vial by using air pressure.28 To wash the vial, add
16.5 mL of DMF stir for 2.5 minutes and drain the DMF.28 Repeat the washing step of the resin
with the DMF 2 more times for 2.5 minutes each.28
5.3.6 SPPS Recipe: Step 6. Coupling of the next amino acid
Before coupling the next amino acid, repeat the Fmoc deprotection and the washing step with
DMF (step 2 and 3). Next, to couple the following amino steps repeat steps 5 and 7. If plan to
continue the synthesis the next day, after the coupling step wash the reaction vial with 16.5 mL
of DMF stir for 2.5 minutes DMF (repeat 2 times).28 And, lastly wash the vial with 16.5 mL of DCM
for 2.5 minutes DCM (repeat 2 times). Dry the reaction vail well and store it away in the freezer.28
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Before staring the deprotection step, allow the reaction vial to warm up to room temperature
and repeat step 1 through 4.
5.3.7 SPPS Recipe: Step 7. Final Wash
Add 16.5 mL of DMF stir for 2.5 minutes and drain the DMF.28 Repeat the washing step of the
resin with the DMF 2 more times for 2.5 minutes each.28 Wash the reaction vial again with DCM.
Add 16.5 mL of DCM stir for 2.5 minutes and drain the DCM.28 Repeat the washing step of the
resin with the DCM 2 more times for 2.5 minutes each.28 Label the reaction vial and store it in
the -20oC freezer.
5.3.8 SPPS Recipe: Step 8. Micro Cleavage
To make 1% TFA cleavage solution, use DCM use as a solvent.28 To perform a micro-cleavage for
the conformation of an intermediate product, take small amount of product from the reaction
vial and transfer it to a HPLC vial with a stir bar. Add 1 mL of the 1% TFA cleavage solution to the
HPLC vial and allow it to stir for 30 minutes. Make a filter by adding small amount of glass wool
to a pipette. Obtain a small dry flask, and filter the 1 mL of the product through the peptide and
wash the filter with about 1 mL of DCM. Lastly, rotovap the filtered product and to assay it add
few drops of methanol to the flask and transfer to a space-saver vial. And evaluate the molecular
weight and UV-VIS chromatogram of each intermediate and final product in the LCMS.
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Chapter 6. Puzzle pieces (Imaging Modules)
6.1 Puzzle Pieces for TMIAs
To synthesize the TMIAs, a new method known as the modular method, developed in our lab,
was applied to attachment of imaging agents to peptides.54 In this method, the targeting
peptide is synthesized first, followed by conjugation of the imaging modules used for MRI and
NIR imaging. The imaging modules are also called puzzle pieces. To synthesize the puzzle
pieces, the imaging groups are placed on the side chain of a lysine amino acid early in the
synthesis. Later in the synthesis the puzzle pieces (with NIR dye and Gd-DOTA) are coupled
to the breast cancer peptide 18-4 by using SPPS.
6.1.1 Gd-DOTA Puzzle Piece for MIR Imaging
The contrast agent gadolinium (Gd) used in MRI, is known to have toxic effects when the
free metal is released in the body.55 To improve Gd bioavailability and excretion in the body a
chelated organic structure is used.55 Dodecane tetraacetic acid (DOTA) is a complexing agent (see
Scheme 4), which is used in cancer imaging.56 By chelating Gd using DOTA, this release is reduced
to such a minimal degree that it allows the use of Gd-DOTA (Dotarem) to be utilized as a contrast
agent.56 However, there is speculation that even tiny amounts of free Gd is formed by kinetic demetalation or trans-metalation by other metals in the bloodstream.
To minimize the safety risks further, the concentration of Gd agent per inject can be vastly
reduced by using targeting agents. Moreover, by using TMIAs the concentration of Gd will be
increased at the tumor site compared to normal cells. To apply the modular method to contrast
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agents for MRI, the Gd-DOTA puzzle piece reaction is below, which is a one pot synthesis and was
developed in our lab.28,56

NMM, TSTU, Gd(OAc)3
DMF

Scheme 4. Modular Synthesis of lysine puzzle piece with Gd-DOTA.56 were R – Osu
(otherwise known as the mono-NHS ester of DOTA.
6.1.2 Near Infrared (NIR) Dye Cy5.5 Puzzle Piece
Previously, in our lab, the first Cy5.5 dye puzzle that was synthesized was composed of three
sulfonates.28 As shown below, the Cy5.5 dye is drawn in blue and the Fmoc group on the lysine
amino acid is drawn in black.28 To synthesize the puzzle piece, the Cy5.5 was activated by using
the coupling agent TSTU, which results in the NHS ester (a good leaving group). Then it was
coupled or conjugated to the side chain amine in a protected lysine.
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Scheme 5. Synthesis of Puzzle Piece with three sulfonates NIR Cy5.5 Dye28,57
In a previous experiment in our lab, Xinyu Zu coupled a tri-peptide (Fmoc-Met-Ile-PheNH2) to the NIR Cy5.5 puzzle piece that was synthesized with three sulfonate groups.28
Disappointingly, that the dye was unable to be cleaved from the resin at the last step of the
synthesis.28 To cleavage the dye from the resin different methods were tested such as using
stronger acid (TFA) concentration, different solvents, and increased cleavage time.28 However,
the cleavage methods were unsuccessful and it was concluded that, having three sulfonate
groups=, the Cy 5.5 dye stuck on the resin irreversibly.28
To improve the cleavage step of the Cy 5.5 dye to the resin, Xinyu used another dye puzzle
piece (shown below).28 This puzzle piece contained the non-sulfonated version of the dye, which
was lipophilic and easier to remove from the resin during the cleavage step.28
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Scheme 6. Synthesis of Puzzle Piece with non-sulfonated NIR Cy5.5 Dye28,57
The non-sulfonated NIR Cy5.5 dye puzzle piece was composed of a free acid on the right
side, which can be used to conjugate to the rest of the peptide in SPPS. In the past, the SPPS was
used to synthesize the breast cancer peptide 18-4 and was coupled to the non-sulfonated NIR
Cy5.5 dye puzzle piece, which resulted in the TMIA product, named M2, shown in Figure 12.28
The non-sulfonated version of the dye, when attached to the peptide, was able to be cleaved and
isolated at the last step with 1% TFA.28
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Figure 12. Deprotected Breast Cancer peptide 18-4 with non-sulfonated Cy5.5 dye (TMIA-M2),
prepared by Xinyu Xu and Matt Law28
A main drawback to the non-sulfonated Cy5.5 dye is that it has low solubility because the
dye is highly lipophilic. Therefore, when making samples for biological testing (CFM imaging) the
M2 TMIA product requires 5-10% of DMSO, which is not an ideal cellular environment for humans
but is okay for in vitro testing. In this work, to increase the water solubility of the Cy5.5 dye, the
sulfonated version of the dye was used. As shown below, the mono-sulfonated NIR Cy5.5 dye
puzzle piece has a net charge of zero on the dye system, but the negative charge on the sulfonate
group will assist the dye solubility in aqueous solution.
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Scheme 7. Synthesis of Lysine Puzzle Piece with one sulfonate NIR Cy5.5 Dye57
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Chapter 7. Results and Discussion
7.1 Breast Cancer Targeting peptide 18-4
The first goal of this work was to use SPPS to produce the breast cancer peptide 18-4,
discovered by Dr. Kaur. The stucture of 18-4 after it’s synthesis on the resin, as shown in Figure
13. The peptide is composed of three protecting groups inducluding a phenylisopropyl (PhiPr) on
glutamic acid, t-butyl (tBu) ether on tyrosine, and methyl trityl (MTT) on lysine. In the earlier work
of Xinyu Xu, a t-butyl ester was utilized on the glutamic acid position. We found that the PhiPr
was more readily deprotected during the cleavage step and is therefore preferred.

Figure 13. Structure of breast cancer peptide 18-4 (with protecting groups) on resin
Using the SPPS method developed in our lab by Xinyu Xu and Matt Law, and further
modified in this research project, the breast cancer peptide 18-4 was sucessfully synthesized by
using the step-by-step experminental SPPS guide expained in Chapter 5.
At each intermeditate step of the synthesis, a small amount of the peptide was cleaved
wih 1% TFA and was assayed with LC-MS. The molecular weight at each intermediate step was
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verified by comparing masses obtained with those in Table 3. The protecting group MTT on dlysine and PhiPr on glutamic acid are removed rapidly during the cleavage process. However, the
t-butyl on tyrosine was the protecting group to be removed last and required longer time
(overnight) to be cleaved.
To verify the identity and purity of the peptide 18-4, high-performance liquid
chromatography-mass spectrometry (LC-MS) was used. Also, to prove the exact molecular
formula of peptide and the TIMAs, high-resolution mass spectrometry (HR-MS) was used. Table
3, shows all the possible intermeditate (monopetide-decapeptide) forms of the breast cancer
peptide 18-4 (with and without protecting groups) with the calculated molecular weights and
half mass.
Ths LC-MS results for all of the breast cancer peptide 18-4 intermediate and products
from the LC-MS are shown in Appendix I, with the parent intermediate peptide numbered (no
numbers on the multiple protected forms) which shows the purity of product and verfies the
correct molecular weight and half mass. For example, the final 18-4 peptide (compound 10 in
Appendix 1) in its Fmoc protected form, Fmoc-trp-dNle-Glu-Ala-Ala-Tyr Gln-dLys-Phe-Leu-NH2
displayed the expected LC-MS results (MW 1488.70 M+H+).
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Figure 14. Stucture of the Breast Cancer Fmoc Peptide 18-4 (10) with no protecting groups
(compound numbers are displayed in Appendix 1 and Table 3)
In Table 3, the molecular weight of each intermediate in it’s protected, partially protected, and
fully deprotected form is listed, along with the “half mass” that is often apparent in mass
spectrometry. The half mass is defined as (M+2)/2 which is when the two protons add to the
molecule to produce a charge of two. As the mass observed in MS is M/Z, where M is molecular
weight and Z is the charge, the molecular weight may often be observed at half mass. This is
particularly useful for very large molecules that may be beyond the range of conventional mass
spectrometers (over 2,000 amu).
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Table 3. Molecular Weight of Fmoc Protected Peptide 18-4 Intermediate Products
Compounds

Molecular
Weight
(g/mol)

Half
Mass
(g/mol)

Fmoc-Leu-NH2 (1)

352.2

177.1

Fmoc-Phe-NH2

386.2

194.1

Fmoc-Phe-Leu-NH2 (2)

499.2

250.6

Fmoc-d-Lys (Mtt)-Phe-Leu-NH2

883.5

442.8

Fmoc-d-Lys-Phe-Leu-NH2 (3)

627.3

314.7

Fmoc-Gln-d-Lys-Phe-Leu-NH2 (4)

755.4

378.7

Fmoc-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2

974.5

488.3

Fmoc-Tyr-Gln-d-Lys-Phe-Leu-NH2 (5)

918.5

460.3

Fmoc-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2

1045.6

523.8

Fmoc-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (6)

989.5

495.8

Fmoc-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2

1116.6

559.3

Fmoc-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (7)

1060.5

531.3

Fmoc-Glu (PhiPr)-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2

1307.6

654.8

Fmoc-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2

1245.6

623.8

Fmoc-Glu (PhiPr)-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2

1363.7

682.8

Fmoc-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (8)

1189.6

595.8

Fmoc-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (9)

1302.7

652.4

Fmoc-d-Nle-Glu (PhiPr)-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2

1420.7

711.3

Fmoc-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2

1358.7

680.4

Fmoc-d-Nle-Glu (PhiPr)-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2

1476.8

739.4

Fmoc-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (10)

1488.7

745.4

Fmoc-Trp-d-Nle-Glu (PhiPr)-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2

1606.8

804.4

Fmoc-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2

1544.8

773.4

Fmoc-Trp-d-Nle-Glu((PhiPr)-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2

1662.8

832.4

46

7.2 Fmoc Deprotected Breast Cancer Targeting peptide 18-4
The Fmoc protected breast cancer peptide 18-4 (Compound 11) was deprotected, by the method
described in Chapter 5.3.2 to remove the Fmoc. Lastly the peptide was cleaved with 1% TFA,
which resulted in the final product as shown below in Figure 15. The product, NH2-Trp-d-NleGlu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (compound 12) shown below was composed of tbutyl on tyrosine (LC-MS results 1323.55 m/z [M+H]+, 662.51 m/z (M+2H+)/2).

Figure 15. Stucture of the Breast Cancer Peptide 18-4 with t-butyl protecting group on tyrosine
(12)
Table 4. Molecular Weight of Fmoc deprotected Peptide 18-4 Products
Compounds
Molecular
Weight (g/mol)
NH2-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2
1266.67
NH2-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2
1322.73
NH2-Trp-d-Nle-Glu (PhiPr)-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2
1384.75
NH2-Trp-d-Nle-Glu (PhiPr)-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2
1426.80
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Half Mass
(g/mol)
634.33
662.36
693.37
714.4

7.3 Synthesis of Single-Modal Breast Cancer TMIA for MRI
The second goal of this research was to synthesize a single-modal breast cancer TMIA for MRI,
where the contrast agent Gd-DOTA was used. The synthesis of the TMIA for MRI is shown in
Scheme 8 where the first step was to deprotect the Fmoc on the 18-4 peptide by using the
method in Chapter 5.3.2. Note the following synthesis was performed on the resin in solid phase
synthesis. Next, the Gd puzzle piece (Fmoc-dLys (Gd-DOTA)-OH) was coupled by following the
method mentioned in Chapter 5.3.6. As a result, the fully9 protected form of Fmoc-Gd-DOTA18-4-NH2 TMIA was produced as the penultimate intermediate.

Polymer

Deprotect Fmoc
t-butyl ether on Tyr methyl trityl on Lys

Couple
Fmoc-dLys(Gd-DOTA)-OH

PhiPr on Glu

Cleave from resin
with 1% TFA in DCM

Polymer

Scheme 8. Synthesis of Single-Modal Imaging Module for MRI, Fmoc-Gd (DOTA)-18-4Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2
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7.4 Fmoc Protected Gd-DOTA labelled breast cancer peptide 18-4 TMIA Product
The second goal to synthesize a single modal TMIA for MRI was successfully achieved and was
assayed with LC-MS. To test the Fmoc protected Gd-DOTA labelled breast cancer 18-4 TMIA agent
was cleaved with 1% TFA. The final product, Fmoc-Gd (DOTA)-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)Gln-d-Lys-Phe-Leu-NH2 is shown below, (LC-MS Results 1080.30 m/z (M+2H+)/2), HRMS Results:
1079.96950 m/z (M+2H+)/2), water adduct also seen at 1087.9636 m/z).

Formula Weight : 2160.5
Exact Mass : 2159.93501
Formula : C 100H137GdN20O24

Figure 16. Stucture of the Fmoc protected Gd(DOTA) lablled Breast Cancer Peptide 18-4 SingleModal TMIA Agent
Table 5. Molecular Weight of Fmoc Protected NH2-Gd (DOTA)-18-4-NH2 Products
Compounds
Fmoc-d-Lys(Gd-DOTA)-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-dLys-Phe-Leu-NH2
Fmoc-d-Lys(Gd-DOTA)-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)Gln-d-Lys-Phe-Leu-NH2
Fmoc-d-Lys(Gd-DOTA)-Trp-d-Nle-Glu(PhiPr)-Ala-Ala-TyrGln-d-Lys-Phe-Leu-NH2
Fmoc-d-Lys(Gd-DOTA)-Trp-d-Nle-Glu(PhiPr)-Ala-AlaTyr(tBu)-Gln-d-Lys-Phe-Leu-NH2
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Molecular Weight
(g/mol)
2159.93

Half Mass
(g/mol)
1080.5

2216.18

1109.09

2278.19

1140.09

2334.26

1168.13

7.5 Fmoc Deprotected Gd (DOTA) labelled breast cancer peptide 18-4 TMIA Product
To obtain the final TMIA product, the Fmoc group on the Gd (DOTA) labelled breast cancer
peptide 18-4 was removed using the method mentioned in Chapter 5. Note that the tbutyl group
required longer cleavage time (overnight), other protecting groups were removed easily with 30minute cleavage.

Formula Weight : 2160.5
Exact Mass : 2159.93501
Formula : C 100H137GdN20O24

Figure 17. Stucture of the Fmoc deprotected Gd(DOTA) lablled Breast Cancer Peptide 18-4
Single-Modal TMIA Agent
Table 6. Molecular Weight of Fmoc deprotected NH2-Gd (DOTA)-18-4-NH2 Products
Compounds
NH2-d-Lys(Gd-DOTA)-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-PheLeu-NH2
NH2-d-Lys(Gd-DOTA)-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-LysPhe-Leu-NH2
NH2-d-Lys(Gd-DOTA)-Trp-d-Nle-Glu(PhiPr)-Ala-Ala-Tyr-Gln-d-LysPhe-Leu-NH2
NH2-d-Lys(Gd-DOTA)-Trp-d-Nle-Glu(PhiPr)-Ala-Ala-Tyr(tBu)-Gln-dLys-Phe-Leu-NH2

50

Molecular
Weight
(g/mol)
1935.85

Half Mass
(g/mol)

1991.91

996.95

2053.93

1027.96

2109.99

1055.99

968.92

To test the deprotected Fmoc Gd-DOTA labelled breast cancer, the Gd- 18-4 probe for
MRI was cleaved with 1% TFA. The final product, NH2-Gd (DOTA)-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)Gln-d-Lys-Phe-Leu-NH2 is shown below, (LC-MS Results 996.26 m/z m/z (M+2H+)/2). AS expected,
the UV-Vis diode array resulted in no characteristic peak at 262 nm for the Fmoc protecting
group. And the peak at 270 nm, represents the absorbance of tryptophan and tyrosine amino
acids present in the peptide 18-4.
7.6 Synthesis of Single-Modal Breast Cancer TMIA with NIR Cy5.5 Dye Puzzle Piece (M3TIMA)
The third goal of this research was to synthesize a single-modal breast cancer TMIA for NIR
fluorescence, where the NIR Cy5.5(1S) dye was used. Note the following synthesis was performed
on the resin in solid phase synthesis. The synthesis of the Cy5.5(1S)-TMIA is shown below, where
the first step was to deprotect the Fmoc on the 18-4 peptide by using the method in Chapter
5.3.2. Next, the Cy5.5(1S) puzzle piece (Fmoc-dLys (Cy5.5-1S)-NHS ester) was coupled by
following the method mentioned in Chapter 5.3.6. As a result, the Fmoc-Cy5.5(1S)-18-4-NH2
TMIA was produced a product.
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Petide 18-4 on SPPS resin
Cy5.5-1S)-NHS ester

P

"M3" !
1) Deprotect Fmoc while on Resi - 1st problem step
2) Cleave from SPPS Resin - 2nd problem step

Scheme 9. Synthesis of Single-Modal Imaging Module for CFM, NH2-Cy5.5(1S)-Trp-d-Nle-GluAla-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (M3 Product)
7.6.1 Single-Modal Breast Cancer TMIA with NIR Cy5.5 Dye Puzzle Piece Reaction Failed
All the following steps mentioned in the previous section were carried out, however the
synthesis was not a success. The single modal TMIA agent for NIR dye was not produced,
instead the product shown below was produced from the synthesis. The following product
resulted a LC-MS peak of 1323 m/Z, and the derived structure of the product was speculated
to be the structure shown below.
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Figure 18. A product from the M3 failed synthesis due to excess coupling agents
The suspected impurity structure in Figure 18 was a result of the peptide reacting with the
coupling agents (TBTU or TSTU) itself used in SPPS. As shown in the Figure below, both of the
agents contain two dimethyl amines attached to a carbon between them as an activating group,
which can react with the peptide. It was concluded that the product was result from the excess
of TSTU or TBTU, therefore the solution was to not use an excess of the coupling agents. As a
result, for SPPS the TSTU was reduced to 1.2 equivalents.

(a)

(b)

Figure 19. Structure of coupling agents used in SPPS (a) TBTU (b) TSTU
7.6.2 Optimization in the Fmoc Deprotection Step of SPPS
Another resaon of the M3-TMIA reaction failed was due to the Fmoc deprotection step in
SPPS. As mentioned in Chapter 5.3.2 to deprotect the Fmoc, a mixture of DBU and piperazine was
used for all the pervious deprotection steps. However, Matt Law discovered that theses
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deprotection reagents (shown below) cause degradation of the Cy5.5(1S) dye. To test the stability
of the dye in the deprotection solution, a seprate reaction was done. To the Cy5.5(1S) dye, the
deprotection was added and the dye changed color from blue to yellow, which indicated that the
piperazine or DBU was causing the dye to degrade.

(a)

(b)

Figure 20. Structure of Fmoc Deprotection agents used in SPPS (a) Piperazine (b) DBU
Another stability test for the dye in the deprotection solution was performed. To the
Cy5.5(1S) dye, a new deprotection solution (DEA) was added and the dye did not change color
from blue to yellow. As a solution for all the future Fmoc deprotection steps the new 10%
DEA (shown below) was used.

N
H

Figure 21. Structure of Fmoc Deprotection agent DEA
7.6.3 Optimization of SPPS steps to improve Single-Modal M3-TMIA Synthesis
After multiple failed reactions, we determined that each step of the SPPS needed to be
evaluated. So, a step-by-step strategy to improve the synthesis for M3-TIMA product was carried
out. Each step was studied carefully and new methods were developed and put in place, as shown
in the Figure 22.
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7.6.3.1 Optimization of Fmoc Deprotection and Washing After Fmoc Deprotection Step
Based on the results described above, when the Cy5.5 was present, several of the SPPS
needed critical changes. The first optimization performed was on the second step of the SPPS,
where a new Fmoc-deprotection reagent was tested. Using diethyl amine (DEA) instead of the
DBU/piperidine method, prevented the Cy5.5(1S) dye degradation. Previously 5% of DEA was
tested, which did not completely remove the Fmoc group. However, it was found that 10% of
DIEA was satisfactory for Fmoc-deprotection. Before continuing the synthesis, it was important
to assay a small amount of the deprotected peptide with LC-MS to prove the deprotection was
successful.
In addition, after the deprotection step, the washing step was also important to optimize.
To ensure that the peptide on resin was not degraded by the basic DEA solution, the reaction vial
was washed well and pH of the eluent was carefully monitored until it was no longer basic. To
check the PH of the eluent, a damp pH paper was used. These changes are shown in the first step
in Figure 22 which summarizes all of the important optimization steps.
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1. Pre-Swelling

2. Fmoc Deprotection
Use 10% DEA and test de-Fmoc Peptide
(previously used 5% piperizine/DBU)
And Prove Fmoc Deprotection
3. Washing After Deprotection
Wash well until eluant is no longer basic
4. Coupling Amino Acids
Prove activation of the dye (with butyl
amine quench)
Check PH of the Cy5.5(1S) dye before
Coupling
Add at least 40 equivalence of DIEA
5. Washing After Coupling

6. Final Wash
Wash Well with DMF and DCM
7. Cleavage

Check Dye Stability in TFA

Figure 22. Steps Taken to Improve Single-Modal M3 TMIA Synthesis
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7.6.3.2 Optimization of Coupling Amino Acid, Final Wash, and Cleavage Step
In addition to optimization of the Fmoc deprotection, it was discovered that optimization
was also required for the amino acid coupling step. As mentioned in Chapter 5.3.2, to activate
the dye DIPEA is used. It was discovered that the pH of the puzzle piece Cy5.5 (1S) dye with the
DIPEA was not basic, and when it is not basic, the free amine can be partially protonated
preventing it from being a nucleophile.
Therefore, checking the pH of the Cy5.5(1S) dye before adding it to the reaction vial for
coupling was a very important step. Compared to other SPPS synthesis performed in the past,
which required 10 equivalence of DIPEA. The puzzle piece Cy5.5(1S) dye required at least 40
equivalence to be basic. Moreover, to ensure the activation of the puzzle piece Cy5.5(1S), the
puzzle piece containing the DIPEA was stirred at least 5-10 minutes.
To prove the activation of the puzzle piece by TSTU to form the intermediate active NHS
ester, a test known as the butyl amine quench was performed, and the reaction is shown below.

Formula Weight : 1027.3
Exact Mass : 1026.46014
Formula : C62H66N4O8S

TSTU, DIPA, NMP

Formula Weight : 1124.4
Exact Mass : 1123.47651
Formula : C66H69N5O10S

Formula Weight : 1082.4
Exact Mass : 1081.53872
Formula : C66H75N5O7S

Test activity with butyl amine
quench of an aliquot

Scheme 10. Butyl Amine Quench of the Cy5.5(1S) Puzzle Piece Reaction
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To test the identity and purity of the puzzle piece containing the Cy5.5(1S) dye, LC-MS
analysis was performed (LCMS Results: Negative Ion 1025.39 m/z [M+H]+, Positive Ion 1027.35
m/z [M+H]+). To test the activation of the puzzle piece by TSU, a butyl amine quench reaction
was carried out prior to it’s addition and evaluated by LC-MS. A small amount (1-2 drops) of the
activated Cy5.5(1S) puzzle piece (after 5 minutes of stirring) was added to a space saver vial,
along with 1-2 drops of butyl amine. And the aliquot was assayed, (LCMS Results: Positive Ion
1082.33 m/z [M+H]+).
Additionally, after the coupling of an amino acid, removal of reagents was ensured by
washing the reaction vial three times with DMF and DCM.
Lastly, the stability of the Cy5.5(1S) dye was tested in 1% TFA to ensure it would be stable
to the mildly acidic cleavage conditions. To the puzzle piece Cy5.5(1S) dye, about 5 mL of 1% TFA
was added. It was found that the dye was stable and did not degrade in 1% TFA. Therefore, it was
concluded that our reaction did not fail due to stability issues of the dye during the cleavage step.
7.6.3.3 New Continuous Flow Cleavage Method for M3 Product
The last step of the SPPS known as the cleavage step, also required improvements
because the product had low yield. Normally, as mentioned earlier, to remove the t-butyl
protecting group, the product was cleaved overnight. However, we observed the blue color was
sticking to the resin and predicted that the TMIA sticks to the resin, possibly due to the dye
adhering to the resin in the 1% TFA and the product could not be removed. Longer cleavage times
did not improve results as the TMIA appeared to bind to the resin. Therefore, it leads to more
dye stuck to resin as observed in the filter (glass wool) during the cleavage process and resulted
in less color being eluted from the resin.
58

A proposed method to improve the elution of the dye analyte was to use a flow of fresh
1% TFA and collecting the sample continuously, which will allow the product to have less time to
bind with the resin. As a result, more color came off the resin compared to the pervious cleavage
method. About 200 mL of 1% TFA was used in this method. Note, that the Fmoc was removed
prior to the continuous TFA cleavage method.
Lastly, to remove the t-butyl protecting group, the eluent was left in the hood to complete
the deprotection of the acid labile protecting group, especially the t-butyl ether on tyrosine which
was always the last group to come off (the MTT being the first and labile group). It was concluded
that this method was a winner, which results in higher yield of the product.

Figure 23. Schematic Representation of the Continuous TFA Cleavage Flow Method
7.6.4 Fmoc Deprotected Cy5.5(1S) labelled breast cancer peptide 18-4 TMIA Product
(M3-TMIA)
After optimizing the SPPS, the goal to synthesize the single-modal M3-TMIA product, for NIR
fluorescence and OMI imaging of BrCa, shown in Figure 24, was successfully achieved and was
assayed with LC-MS.
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In the initial (non-continuous flow) method of cleavage with 1 % TFA, the de-protected
Fmoc Cy5.5(1S) labelled breast cancer 18-4 TMIA agent M3, NH2-Cy5.5(1S)-Trp-d-Nle-Glu-AlaAla-Tyr-Gln-d-Lys-Phe-Leu-NH2 (first line in Table 7 below) was the resulting product, (LC-MS in
negative ion, 1025.72 m/z (M+2H+)/2 and positive ion 1027.60 m/z (M+2H+)/2). As expected, the
UV-Vis diode array resulted in no characteristic peak at 262 nm for the Fmoc protecting group.
And the peak at 270 nm, shows the absorbance of tryptophan and tyrosine amino acids, which
are present in the peptide 18-4.
In the improved, continuous TFA flow method yielded a much better yield of the same
product, M3 (LC-MS Results: negative ion 1026.04 m/z (M+2H+)/2, positive ion 1027.66 m/z
(M+2H+)/2), HRMS Results: positive ion 1027.468 m/z (M+2H+)/2).

Figure 24. Stucture of the Fmoc deprotected Cy5.5(1S) lablled Breast Cancer Peptide 18-4 SingleModal TMIA Agent (M3 Product)
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Table 7. Molecular Weight of Fmoc deprotected NH2-Cy5.5(1S)-18-4-NH2 Products
Compounds
NH2-d-Lys (Cy5.5)-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-LeuNH2
NH2-d-Lys (Cy5.5)-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-PheLeu-NH2
NH2-d-Lys (Cy5.5)-Trp-d-Nle-Glu (PhiPr)-Ala-Ala-Tyr-Gln-d-Lys-PheLeu-NH2
NH2-d-Lys (Cy5.5)-Trp-d-Nle-Glu (PhiPr)-Ala-Ala-Tyr(tBu)-Gln-dLys-Phe-Leu-NH2

Molecular
Weight
(g/mol)
2053.05

Half Mass
(g/mol)

2111.13

1056.56

2173.15

1087.57

2229.21

1115.60

1027.52

7.7 Synthesis of Dual-Modal TMIA (Fmoc-Gd (DOTA)-Cy5.5(1S)-18-4-NH2)
The last goal of this research was to synthesize a dual-modal breast cancer TMIA for NIR
fluorescence and MRI, containing both the NIR Cy5.5(1S) dye and the MRI contrast agent Gd. It
is important to note that this is the first time (to our knowledge) that the modular method was
utilized to introduce two different imaging modules (puzzle pieces) onto a peptide using SPPS. In
this case, therefore, the entire synthesis of the dual modal TMIA was performed on the resin in
solid phase synthesis.
The synthesis of the Gd (DOTA)-Cy5.5(1S)-TMIA is shown below, where the first step was to
deprotect the Fmoc on the 18-4 peptide by using the method in Chapter 5.3.2. Next, the Cy5.5(1S)
puzzle piece (Fmoc-dLys (Cy5.5-1S)-NHS ester) was coupled by following the method mentioned
in Chapter 5.3.6. As a result, the Fmoc-Cy5.5(1S)-18-4-NH2 TMIA was produced an intermediate
product, which was followed by the removal of the Fmoc group. And lastly the Gd (DOTA) puzzle
piece was coupled next, which resulted in the final dual-modal product.
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14-Step Solid Phase
Peptide Synthesis (SPPS)

Polymer

Protecting groups:
methyl trityl on Lys
t-butyl ether on Tyr
phenyl propyl ester on Glu

Couple second NIR dye puzzle piece

Deprotect Fmoc to creat final TMIA

Cleave from Resin

Scheme 11. Synthesis of Dual-Modal Imaging Module for CFM and MRI, Fmoc-Gd (DOTA)Cy5.5(1S)-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (Dual Modal TMIA Product)
7. 8 Fmoc Protected Gd (DOTA) and Cy5.5(1S) labelled breast cancer peptide 18-4 TMIA
Product (Dual-Modal TMIA)
All the optimization methods for SPPS were used to synthesize the dual-modal TMIA
product for NIR fluorescence and MIR, which was successfully achieved and was assayed with LCMS. To test the Fmoc protected Gd-DOTA and Cy5.5(1S) labelled breast cancer 18-4 TMIA agent
was cleaved with 1% TFA. The final product, Fmoc-Gd (DOTA)-Cy5.5(1S)-Trp-d-Nle-Glu-Ala-Ala-
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Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 is shown below, (LC-MS Results: 1473.97 m/z (M+2H+)/2 and
982.05 m/z (M+3H+)/3).

Formula Weight : 2882
Exact Mass : 2881.38262
Formula : C 148H194GdN24O26

Figure 25. Stucture of the Fmoc protected Gd(DOTA) and Cy5.5(1S) lablled Breast Cancer
Peptide 18-4 Single-Modal TMIA Agent
Table 8. Molecular Weight of Fmoc protected Fmoc-Gd (DOTA)-Cy5.5(1S)-18-4-NH2 Products
Compounds
Fmoc-d-Lys (Cy5.5)-d-Lys (Gd-DOTA)-Trp-d-Nle-Glu-Ala-Ala-TyrGln-d-Lys-Phe-Leu-NH2
Fmoc-d-Lys (Cy5.5)-d-Lys (Gd-DOTA)-Trp-d-Nle-Glu-Ala-AlaTyr(tBu)-Gln-d-Lys-Phe-Leu-NH2
Fmoc-d-Lys (Cy5.5)- d-Lys (Gd-DOTA)-Trp-d-Nle-Glu (PhiPr)-AlaAla-Tyr-Gln-d-Lys-Phe-Leu-NH2
Fmoc-d-Lys (Cy5.5)- d-Lys (Gd-DOTA)-Trp-d-Nle-Glu (PhiPr)-AlaAla-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2
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Molecular
Weight
(g/mol)
2881.38

Half Mass
(g/mol)

2944.01

1473.00

2999.45

1500.72

3055.52

1528.76

1441.69

Chapter 8. Conclusion
The modular method developed in our lab was found to be a useful method to synthesize
single-modal and dual-modal peptide-based TMIAs. The solid phase peptide synthesis (SPPS)
developed previously by Xinyu Xu using the Sieber resin was further modified to facilitate
coupling of dyes. The first goal of this research, which was to synthesize a BrCa targeting peptide
18-4, reported by Dr. Kaur (who used Rink amide resin) was successfully achieved. The TMIA’s
that were synthesized will thus be selective for breast cancer cells.
The next goal of this research was to use the modular method and imaging puzzle pieces
to synthesize single-modal TMIA’s for NIR dye (Cy5.5(1S)) and MRI contrast agent (Gd), which
was successfully achieved. The Sieber resin proved to be an effective solution for the use of
cyanine dyes such as Cy5.5, which would otherwise decompose in the presence of pure TFA which
is necessary to cleave a peptide from Rink resin by allowing cleavage in dilute, 1 % TFA in DCM in
which these dyes are stable.
In the first synthesis, the puzzle piece containing Gd-DOTA, attached to a lysine side
chain, was used to couple to the Fmoc-deprotected BrCa targeting peptide 18-4, which was
followed by the same 1 % TFA cleavage method to provide a Gd-based single modal TMIA agent
for MRI. This validates the approach of utilizing SPPS to couple a chelated metal to a growing
peptide chain using SPPS.
In the next campaign, the dye Cy5.5 dye on the side chain of lysine was assembled by the
modular method into a new TMIA for BrCa known as M3. The synthesis of M3 required critical
optimization of the SPPS methods on the resin. The deprotection of the Fmoc was optimized,
where a new Fmoc deprotection method was used that did not degrade the Cy5.5 (1S) dye. The
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activation step of the NIR dye puzzle piece for coupling was optimized, where the equivalents of
DIPEA was increased. Lastly, the cleavage step of the SPPS method was optimized. A new method
known as the continuous flow of TFA cleavage method was developed, which solved the binding
of the dye to the resin and resulted in higher yield. The TMIA M3was delivered to biologists for
evaluation in cell binding and CFM experiments.
The ultimate goal of this research was to use the modular method to synthesize a dualmodal imaging agent for NIR fluorescence and MRI contrast agent. This was successfully achieved
and represents the first time that two imaging moieties were brought in to a peptide using SPPS
methodology. These critical improvements in the SPPS methods will be vital for future dye TMIA
synthesis in our group. Our lab’s future goal is to synthesize a single PDT and dual modal NIR-PDT
agents that will be useful for breast cancer therapy. The hope is that these methods used to
synthesize selective TMIAs for breast cancer will not only detect cancer at an early stage but also
kill the cancer.
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Chapter 9. Experimental Procedures
9.1 Materials and Methods
Chemicals were purchased from VWR (Radnor, PA), Sigma Aldrich (St. Louis, MO), Alfa
Aesar (Ward Hill, MA), TCI (Tokyo, Japan), and Acros Organics (Morris Plains, NY), and were used
as received unless otherwise stated. All were HPLC or American Chemical Society grade. Amino
acid starting materials and Xanthenyl linker resin were purchased from Bachem (Bubendorf,
Switzerland), and Chem-Impex Int’l Inc. (Wood Dale, IL). DOTA was purchased from Macrocyclics
(Houston, TX).
The HPLC instrument used was an Agilent 1100 with Diode Array Detector and for LC-MS
a Waters 2695 Alliance HPLC with a Waters 2998 Diode Array Detector and a Waters 3100 SQ
Mass Spectrometer was used. For HPLC the columns used were: an Agilent XDB C18 column, with
dimensions of 3 mm x 100 mm or a Waters XBridge C18 column 50 mm x 3 mm and 3μ particle
size. Mass spectra from this instrument were recorded at unit resolution with positive and
negative switching mode at 35 or 50 V cone voltages. The flow rate for HPLC-MS was 0.5 mL/min.
All aqueous mobile phases for HPLC are 0.1M ammonium acetate unless otherwise noted.
Preparative HPLC (prep-HPLC) was carried out with a Waters 600E system controller, and
Waters 600 multi-solvent delivery system using a 30 mL/min flow rate. For SPE purification, a 20
g C-18 Sep-pack Varian Mega Bond Elut (20CC/5GRM) SPE cartridge was utilized for DCL (7).
Aqueous mobile phases for prep-HPLC are 0.1M ammonium acetate unless otherwise
noted. Aqueous mobile phases for SPE are not buffered unless otherwise noted. The SPE
cartridges were conditioned with their respective organic solvent, then pure DI H2O, then
equilibrated with the initial gradient concentration. Gradients were performed in 5% increments
with 3-10 mL fractions each unless otherwise noted.
High resolution mass spectra (HRMS) were obtained on a Waters Synapt G2Si (School of
Chemical Sciences, University of Illinois at Urbana-Champaign) using the following parameters:
Flow injection at flow rate of 0.1 ml/min, H2O/ACN/0.1% Formic Acid, positive and negative
mode ESI, Cone voltage =25 V, capillary voltage = 3.0, ion source temperature = 100°C,
desolvation temperature =180 °C, nebulizing gas (N2) flow = 200 L/h, cone gas (N2) flow = 5L/h.
9.2 Experimental Procedures
Fmoc-Leu-NH2 (1) Xanthenyl linker resin (850 mg, 247.35 µmol) was pre-swelled in DMF (16.5
mL). This reaction was stirred for 20 minutes and was drained using air pressure. After draining,
to the reaction vial the Fmoc deprotection solution (8.5 mL of 5% Piperazine, 2% DBU, 93% DMF)
was added and was stirred for 5 minutes. To the resin the deprotection step was repeated three
times. The reaction vail was washed three times with DMF (16.5 mL). To a 20 mL scintillation vial
the amino acid, Fmoc-Leu-OH (174.8 mg, 494.7 µmol) was dissolved in DMF (16.5), followed by
the addition of DIEA (569 µL, 2473.5 µmol). To a separate 20 mL scintillation vial, HATU (178.6
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mg, 469.9 µmol) was dissolved in DMF (16.5 mL) and was added to the amino acid mixture and
stirred for 5 minutes. Then the mixture was added to the reaction vial and was allowed to stir for
45 minutes at room temperature. After 45 minutes of coupling, the solution was drained and the
reaction was washed with DMF (16.5 mL) three times and was followed up by DCM (16.5 mL)
three times. A small amount of the resultant resin (1R) (10 µg), was removed from the reaction
vial and was cleaved with 1% TFA in DCM (1 mL) for 30 minutes. The product was filtered through
glass wool and washed with DCM (1 mL). The eluent was concentrated with a rotovap, dissolved
in 0.5 mL of methanol and assayed by LC-MS. LC-MS (LR, ESI) = Calcd. For C21H24N2O3: 352.178
m/z, found: 353.10 [M+H]+.
Fmoc-Phe-Leu-NH2 (2). Resin 1R was treated by the same procedure as for (1) about using the
amino acid, Fmoc-Phe-OH (191.64 mg, 494.7 µmol), followed by cleavage of a small amount of
the resultant resin (2R) also by the same procedure as above to yield Fmoc-Phe-Leu-NH2 (2). LCMS. LC-MS (LR, ESI) = Calcd. For C30H33N3O4: 499. 247 m/z, found: 500.11 [M+H]+.
Fmoc-d-Lys-Phe-Leu-NH2 (3). Resin 2R was treated by the same procedure as for (1) about using
the amino acid, Fmoc-d-Lys (MTT)-OH (249.45 mg, 494.7 µmol), followed by cleavage of a small
amount of the resultant resin (3R) also by the same procedure as above to yield Fmoc-d-Lys-PheLeu-NH2 (3). LC-MS. LC-MS (LR, ESI) = Calcd. For C36H45N5O5: 627.34 m/z, found: 628.22 [M+H]+.
Fmoc-Gln-d-Lys-Phe-Leu-NH2 (4). Resin 3R was treated by the same procedure as for (1) about
using the amino acid, Fmoc-Gln-OH (191.14 mg, 494.7 µmol), followed by cleavage of a small
amount of the resultant resin (4R) also by the same procedure as above to yield Fmoc-Gln-d-LysPhe-Leu-NH2 (4). LC-MS. LC-MS (LR, ESI) = Calcd. For C41H53N7O7: 755.40 m/z, found: 756.20
[M+H]+.
Fmoc-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (5). Resin 4R was treated by the same procedure as for
(1) about using the amino acid, Fmoc-Tyr(tBu)-OH (227.36 mg, 494.7 µmol), followed by cleavage
of a small amount of the resultant resin (5R) also by the same procedure as above to yield FmocTyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (5). LC-MS. LC-MS (LR, ESI) = Calcd. For C54H70N8O9: 974.52 m/z,
found: 975.16 [M+H]+.
Fmoc-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (6). Resin 5R was treated by the same procedure as
for (1) about using the amino acid, Fmoc-Ala-OH (154.0 mg, 494.7 µmol), followed by cleavage
of a small amount of the resultant resin (6R) also by the same procedure as above to yield FmocAla-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (6). LC-MS. LC-MS (LR, ESI) = Calcd. For C57H75N9O10: 1045.56
m/z, found: 1046.23 [M+H]+.
Fmoc-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (7). Resin 6R was treated by the same procedure
as for (1) about using the amino acid, Fmoc-Ala-OH (154.0 mg, 494.7 µmol), followed by cleavage
of a small amount of the resultant resin (7R) also by the same procedure as above to yield FmocAla-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (7). LC-MS. LC-MS (LR, ESI) = Calcd. For C60H80N10O11:
1116.60 m/z, found: 1117.20 [M+H]+.
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Fmoc-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (8). Resin 7R was treated by the same
procedure as for (1) about using the amino acid, Fmoc-Glu (PhiPr)-OH (210.48 mg, 494.7 µmol),
followed by cleavage of a small amount of the resultant resin (8R) also by the same procedure as
above to yield Fmoc-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (8). LC-MS. LC-MS (LR, ESI) =
Calcd. For C65H87N11O14: 1245.64 m/z, found: 1246.22 [M+H]+.
Fmoc-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (9). Resin 8R was treated by the same
procedure as for (1) about using the amino acid, Fmoc-d-Nle-OH (174.82 mg, 494.7 µmol),
followed by cleavage of a small amount of the resultant resin (9R) also by the same procedure as
above to yield Fmoc-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (9). LC-MS. LC-MS (LR,
ESI) = Calcd. For C71H96N12O15: 1358.72 m/z, found: 1359.38 [M+H]+.
Fmoc-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (10). Resin 9R was treated by the same
procedure as for (1) about using the amino acid, Fmoc-Trp-OH (260.5 mg, 494.7 µmol), followed
by cleavage of a small amount of the resultant resin (10R) also by the same procedure as above
to yield Fmoc-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (10). LC-MS (LR, ESI) = Calcd. For
C78H100N14O16: 1488.74 m/z, found: 1489.71 [M+H]+.
Fmoc-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (11). Resin 9R was treated by the
same procedure as for (1) about using the amino acid, Fmoc-Trp-OH (260.5 mg, 494.7 µmol),
followed by cleavage of a small amount of the resultant resin (11R) also by the same procedure
as above to yield Fmoc-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (10). LC-MS (LR,
ESI) = Calcd. For C82H108N14O16: 1544.80 m/z, found: 1545.44 [M+H]+.
NH2-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (12). Resin 11R was treated with
Fmoc deprotection method, which was followed by cleavage of the resultant resin (12R) also by
the same procedure as above to yield NH2-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-LeuNH2 (12). LC-MS (LR, ESI) = Calcd. For C67H98N14O14: 1322.73 m/z, found: 1323.55 [M+H]+, found:
662.51 (M+2H+)/2. HRMS: Calcd. MW 1322.73869, (M+1): 1323.74663, [(M+2)/2]: 662.37729,
Found 662.3759 (- 2.09 ppm).
Fmoc-Gd (DOTA)-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (13). Small amount of resin
12R (30 mg) was treated by the same procedure as for (1) about using the puzzle piece, Fmoc-dLys (Gd-DOTA)-NH2 (15.21 mg, 87.3 µmol), followed by cleavage of the resultant resin (13R) also
by the same procedure as above to yield Fmoc-Gd (DOTA)-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-LysPhe-Leu-NH2 (13). LC-MS (LR, ESI) = Calcd. for C100H135GdN20O24: MW 2157.9199, (M+1): 2158.93;
[(M+2)/2]: 1079.97; found: 1080.30 m/z (M+2H+)/2. HRMS: Calcd. MW 2157.9199, (M+1):
2158.92786; [(M+2)/2]: 1079.96790, Found 1079.96950 (- 1.48 ppm).
NH2-Gd (DOTA)-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (14). Resin 13R was treated
by Fmoc deprotection method, followed by cleavage of the resultant resin (14R) also by the same
procedure as above to yield NH2-Gd (DOTA)-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2
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(14). LC-MS (LR, ESI) = Calcd. For C85H125GdN20O22: 996 m/z, ½ mass 1080.5, found: 996.26 m/z
(M+2H+)/2.
Fmoc-D-Lys(Cy5.5-1S)-OH (Cy5.51S Puzzle Piece) (15). This imaging module was prepared by a
method published by our group.57 LC-MS (LR, ESI) = Calcd. For C62H66N4O8S1: (M+1)+: 1027.47 m/z,
½ mass,
found: 1027.60 m/z. HRMS: Calcd. MW 1026.46014, (M+1): 1027.46808,
Found 1027.4653 (- 2.71 ppm).
Fmoc-D-Lys(Cy5.5-1S)-NHS (Activated Cy5.51S Puzzle Pieces NHS ester) (16). The activation of
imaging module Fmoc-D-Lys(Cy5.5-1S)-OH was carried out using TSTU by a method published by
our group.57 In order to test the activation, a small aliquot of the product was quenched by
dissolved in a solution of 0.1 % butyl amine to yield the butyl amide which was assayed by LCMS. The conversion to activated ester was over 99 % complete. LC-MS (LR, ESI) = Calcd. For
C66H75N5O7S1: (M+1)+: 1082.54 m/z, ½ mass , found: 1082.33 m/z.
NH2-Cy5.5(1S)-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (17). Small amount of resin
12R (30 mg) was treated by the same procedure as for (1) about using the puzzle piece, Fmoc-dLys (Cy5.5(1S))-NH2 (14.5 mg, 13.09 µmol), followed by cleavage of the resultant resin also by the
same procedure as above to yield Fmoc-Cy5.5(1S)-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-LeuNH2. The resultant resin was treated by Fmoc deprotection method, followed by cleavage of the
resultant resin (15R) also by the same procedure as above to yield NH2-Cy5.5(1S)-Trp-d-Nle-GluAla-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (17). LC-MS (LR, ESI) = Calcd. For C110H144N18O19S1: 2158.92
m/z, ½ mass 1027.53, found: 1027.60 m/z (M+2H+)/2. HRMS: Calcd. MW 2053.05759, (M+1):
2054.06553, [(M+2)/2]: 1027.53674, Found 1027.5366 (- 1.31 ppm).
Fmoc-Gd (DOTA)--Cy5.5(1S)-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-Leu-NH2 (18). Resin
15R was treated by the same procedure as for (1) about using the puzzle piece Fmoc-d-Lys (GdDOTA)-NH2 (15.21 mg, 87.3 µmol), followed by cleavage of the resultant resin (16R) also by the
same procedure as above to yield Fmoc-Gd (DOTA)--Cy5.5(1S)-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)Gln-d-Lys-Phe-Leu-NH2 (18). LC-MS (LR, ESI) = Calcd. For C110H145N18O19S: 3053.50 m/z, ½ mass
1472, 1⁄3 mass 981, found: 1473.97 m/z (M+2H+)/2, 982.05 m/z (M+3H+)/3.
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Appendix I. HPLC-MS and HRMS Results
Compound 1: Fmoc-Leu-NH2 (SPPS intermediate monopeptide product of 18-4)

Single Wavelength Chromatogram of 1 at 263 nm of main peak at 5.46 min

UV-Vis Diode array of 1 spectrum at 5.46 min with characteristic peak at 263 nm for Fmoc
protecting group

74

Positive Ion Mass spectrum of 1 at 5.46 min, product 353.10 m/z [M+H]+

Extracted (Single) Ion Chromatogram (XIC) at 353 amu

75

Total Ion Chromatogram (TIC) of 1
Compound 2: Fmoc-Phe-Leu-NH2 (SPPS intermediate dipeptide product of 18-4)

Single Wavelength Chromatogram of 2 at 263 nm of main peak at 4.28 min
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UV-Vis Diode array of 2 spectrum at 4.28 min with characteristic peak at 263 nm for Fmoc
protecting group

Positive Ion Mass spectrum of 2 at 4.28 min, product 500.11 m/z [M+H]+
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Extracted (Single) Ion Chromatogram (XIC) at 500 amu

Total Ion Chromatogram (TIC) of 2

78

Compound 3: Fmoc-dLys-Phe-Leu-NH2 (SPPS intermediate tripeptide product of 18-4)

Single Wavelength Chromatogram of 3 at 263 nm of main peak at 3.53 min

UV-Vis Diode array of 3 spectrum at 3.53 min with characteristic peak at 263 nm for Fmoc
protecting group
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Positive Ion Mass spectrum of 3 at 3.53 min, product 628.22 m/z [M+H]+

Extracted (Single) Ion Chromatogram (XIC) at 628 amu

80

Total Ion Chromatogram (TIC) of 3

Compound 4: Fmoc-Gln-dLys-Phe-Leu-NH2 (SPPS intermediate tetrapeptide product of 18-4)

Single Wavelength Chromatogram of 4 at 263 nm of main peak at 2.13 min
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UV-Vis Diode array of 4 spectrum at 2.13 min with characteristic peak at 263 nm for Fmoc
protecting group

Positive Ion Mass spectrum of 4 at 2.13 min, product 756.20 m/z [M+H]+

82

Extracted (Single) Ion Chromatogram (XIC) at 756 amu

Total Ion Chromatogram (TIC) of 4

83

Compound 5: Fmoc-Tyr Gln-dLys-Phe-Leu-NH2 (SPPS intermediate pentapeptide product of
18-4)

Single Wavelength Chromatogram of 5 at 263 nm of main peak at 4.51 min

UV-Vis Diode array of 5 spectrum at 4.51 min with characteristic peak at 263 nm for Fmoc
protecting group
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Positive Ion Mass spectrum of 5 at 4.51 min, product 975.16 m/z [M+H]+

Extracted (Single) Ion Chromatogram (XIC) at 975 amu
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Total Ion Chromatogram (TIC) of 5

Compound 6: Fmoc-Ala-Tyr Gln-dLys-Phe-Leu-NH2 (SPPS intermediate hexapeptide product of
18-4)

Single Wavelength Chromatogram of 6 at 263 nm of main peak at 4.22 min
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UV-Vis Diode array of 6 spectrum at 4.22 min with characteristic peak at 263 nm for Fmoc
protecting group

Positive Ion Mass spectrum of 6 at 4.22 min, product 1046.23 m/z [M+H]+
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Extracted (Single) Ion Chromatogram (XIC) at 1046.23 amu

Total Ion Chromatogram (TIC) of 6

88

Compound 7: Fmoc- Ala-Ala-Tyr Gln-dLys-Phe-Leu-NH2 (SPPS intermediate heptapeptide
product of 18-4)

Single Wavelength Chromatogram of 7 at 263 nm of main peak at 4.17 min

UV-Vis Diode array of 7 spectrum at 4.17 min with characteristic peak at 263 nm for Fmoc
protecting group
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Positive Ion Mass spectrum of 7 at 4.17 min, product 1117.20 m/z [M+H]+

Extracted (Single) Ion Chromatogram (XIC) at 1117.20 amu

90

Total Ion Chromatogram (TIC) of 7

Compound 8: Fmoc- Glu-Ala-Ala-Tyr Gln-dLys-Phe-Leu-NH2 (SPPS intermediate octapeptide
product of 18-4)

Single Wavelength Chromatogram of 8 at 263 nm of main peak at 1.54 min
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UV-Vis Diode array of 8 spectrum at 1.54 min with characteristic peak at 263 nm for Fmoc
protecting group

Positive Ion Mass spectrum of 8 at 1.54 min, product 1246.22 m/z [M+H]+
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Extracted (Single) Ion Chromatogram (XIC) at 1246.22 amu

Total Ion Chromatogram (TIC) of 8
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Compound 9: Fmoc-dNle-Glu-Ala-Ala-Tyr Gln-dLys-Phe-Leu-NH2 (SPPS intermediate
nonapeptide product of 18-4)

Single Wavelength Chromatogram of 9 at 263 nm of main peak at 1.56 min

UV-Vis Diode array of 9 spectrum at 1.56 min with characteristic peak at 263 nm for Fmoc
protecting group
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Positive Ion Mass spectrum of 9 at 1.56 min, product 1359.38 m/z [M+H]+

Extracted (Single) Ion Chromatogram (XIC) at 1359.38 amu

95

Total Ion Chromatogram (TIC) of 9

Compound 10: Fmoc-trp-dNle-Glu-Ala-Ala-Tyr Gln-dLys-Phe-Leu-NH2 (SPPS decapeptide
product of 18-4)

Single Wavelength Chromatogram of 10 at 263 nm of main peak at 1.91 min
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UV-Vis Diode array of 10 spectrum at 1.91 min with characteristic peak at 263 nm for Fmoc
protecting group

Positive Ion Mass spectrum of 10 at 1.91 min, product 1489.71 m/z [M+H]+,
756.25 m/z (M+2H+)/2, No protecting group on the 18-4
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Extracted (Single) Ion Chromatogram (XIC) at 1488.70 amu

Total Ion Chromatogram (TIC) of 10

98

Compound 11: Fmoc-trp-dNle-Glu-Ala-Ala-Tyr(tBu)-Gln-dLys-Phe-Leu-NH2 (SPPS decapeptide
product of 18-4)

Single Wavelength Chromatogram of 11 at 263 nm of main peak at 2.08 min

UV-Vis Diode array of 11 spectrum at 2.08 min with characteristic peak at 263 nm for Fmoc
protecting group
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Positive Ion Mass spectrum of 11 at 2.08 min, product 1545.44 m/z [M+H]+,
736.82 m/z (M+2H+)/2, tButyl protecting group on tyrosine

Extracted (Single) Ion Chromatogram (XIC) at 1545.44 amu

100

Total Ion Chromatogram (TIC) of 11
Compound 12: NH2-trp-dNle-Glu-Ala-Ala-Tyr(tBu)-Gln-dLys-Phe-Leu-NH2 (SPPS decapeptide
product of 18-4)

Single Wavelength Chromatogram of 12, main peak at 1.45 min
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UV-Vis Diode array of 12 spectrum at 1.45 min with no characteristic peak at 263 nm for Fmoc
protecting group, Tryptophan and Tyrosine absorb at 270 nm

Positive Ion Mass spectrum of 12 at 1.45 min, product 1323.55 m/z [M+H]+,
662.51 m/z (M+2H+)/2, tButyl protecting group on tyrosine
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Extracted (Single) Ion Chromatogram (XIC) at 1323.55 amu

HRMS Positive Ion Mass Spectra of product 12 (Calc. MW 1322.73869, ½ mass 662.37729,
Found 662.3759)
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Compound 13: Fmoc-Gd(DOTA)-trp-dNle-Glu-Ala-Ala-Tyr(tBu)-Gln-dLys-Phe-Leu-NH2 (Single
Modal TMIA for MRI)

Single Wavelength Chromatogram of 13, main peak at 1.99 min

UV-Vis Diode array of 13 spectrum at 1.99 min with characteristic peak at 265 nm for Fmoc
protecting group
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Positive Ion Mass spectrum of 13 at 1.99 min, product 1080.30 m/z (M+2H+)/2

Extracted (Single) Ion Chromatogram (XIC) at 1080 amu
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HRMS Positive Ion Mass Spectra of product 13 (Calc. MW 2157.91992, ½ mass 1079.96790,
Found 1079.9695 m/z (M+2H+)/2), water adduct also seen at 1087.9636 m/z)
Compound 14: NH2-Gd (DOTA)-trp-dNle-Glu-Ala-Ala-Tyr(tBu)-Gln-dLys-Phe-Leu-NH2 (Single
Modal TMIA for MRI)

Single Wavelength Chromatogram of 14, main peak at 1.99 min
106

UV-Vis Diode array of 14 spectrum at 1.99 min with no characteristic peak at 263 nm for Fmoc
protecting group, Tryptophan and Tyrosine absorb at 270 nm

Positive Ion Mass spectrum of 14 at 1.99 min, product 996.26 m/z (M+2H+)/2
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Extracted (Single) Ion Chromatogram (XIC) at 996.26 amu

Total Ion Chromatogram (TIC) of 14
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Compound 15: Cy5.5(1S) Puzzle piece

Single Wavelength Chromatogram of 15, main peak at 1.32 min

UV-Vis Diode array of 15 spectrum at 1.32 min with characteristic peak at 682 nm for Cy5.5(1S)
dye
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Negative Ion Mass spectrum of 15 at 1.32 min, product 1025.39 m/z (M+2H+)/2

Extracted (Single) Ion Chromatogram (XIC) for Negative Ion at 1025 amu
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Negative Ion Total Ion Chromatogram (TIC) of 15

Positive Ion Mass spectrum of 15 at 1.32 min, product 1027.35 m/z (M+2H+)/2
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Extracted (Single) Ion Chromatogram (XIC) for Positive Ion at 1027.35 amu

Positive Ion Total Ion Chromatogram (TIC) of 15
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HRMS Positive Ion Mass Spectra of product 15 (Calc. MW 1027.46808,Found 1027.4653 m/z)
Compound 16: Butyl Amine Quench

Single Wavelength Chromatogram of 16, main peak at 2.88 min
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UV-Vis Diode array of 15 spectrum at 2.88 min with characteristic peak at 680 nm for Cy5.5(1S)
Dye

Positive Ion Mass spectrum of 16 at 2.88 min, product 1082.33 m/z [M+H]+
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Extracted (Single) Ion Chromatogram (XIC) for Positive Ion at 1082.33 amu

Positive Ion Total Ion Chromatogram (TIC) of 16
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Compound 17: NH2-Cy5.5(1S)-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (M3-TMIA
Product)

Single Wavelength Chromatogram of 17 at 680 nm, main peak at 4.73 min

UV-Vis Diode array of 17 spectrum at 4.73 min with characteristic peak at 680 nm for Cy5.5(1S)
dye
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Positive Ion Mass spectrum of 17 at 4.73 min, product 1027.60 m/z (M+2H+)/2

Extracted (Single) Ion Chromatogram (XIC) for Positive Ion at 1027.60 amu
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Negative Ion Mass spectrum of 17 at 4.73 min, product 1025.72 m/z (M+2H+)/2

Compound 17: NH2-Cy5.5(1S)-Trp-d-Nle-Glu-Ala-Ala-Tyr-Gln-d-Lys-Phe-Leu-NH2 (M3-TMIA
Product for Continuous TFA Cleavage Method)

Single Wavelength Chromatogram of 17, main peak at 5.03 min
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UV-Vis Diode array of 17 spectrum at 5.03 min with characteristic peak at 679.53 nm for
Cy5.5(1S) dye

Positive Ion Mass spectrum of 17 at 5.03 min, product 1027.66 m/z (M+2H+)/2
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Positive Ion Extracted (Single) Ion Chromatogram (XIC) for Positive Ion at 1027.66 amu

Negative Ion Mass spectrum of 17 at 5.03 min, product 1026.04 m/z (M+2H+)/2
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HRMS Positive Ion Mass Spectra of product 17 (Calc. MW 2053.05759, ½ mass 1027.53674,
Found 1027.5370)
Compound 18: Fmoc-Gd(DOTA)-Cy5.5(1S)-Trp-d-Nle-Glu-Ala-Ala-Tyr(tBu)-Gln-d-Lys-Phe-LeuNH2 (Dual Modal Product)

Single Wavelength Chromatogram of 18 at 680, main peak at 4.59 min
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UV-Vis Diode array of 18 spectrum at 4.59 min with characteristic peak at 680.53 nm for
Cy5.5(1S) dye

Positive Ion Mass spectrum of 18 at 4.59 min, product 1473.97 m/z (M+2H+)/2 and 982.05 m/z
(M+3H+)/3
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Positive Ion Mass spectrum of 18 at 4.59 min, product 1472 m/z (M+2H+)/2 (showing Gd Trend)

Positive Ion Mass spectrum of 18 at 4.59 min, product 982.05 m/z (M+3H+)/3 (showing Gd
Trend)
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